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PREFACE 
This study was conducted with the support of the Combined Breast Clinic at 
our institution which consists of the Departments of Surgery, Radiology and 
Radiation Oncology. 
The work was done in three parts. 
The literature showed somewhat lengthy imaging procedure for 
scintimammography which were not whole suitable to the setting of the Combined 
Breast Clinic. Initially a Pilot Study was conducted to determine the practicality of the 
imaging procedure. The results of this study were promising but the imaging 
procedure was time consuming. Certain modifications were subsequently done in the 
imaging method of the Formal Study to accommodate more number of patients into 
the study without jeopardizing the quality of the images. This study, however, had a 
shortcoming in that the way this study was structured one could not demonstrate 
lesion by lesion analysis of each breast lesion detected on clinical examination, 
mammography and scintimammography with their respective biopsy results. Our 
Formal Study and the literature suggested that scintimammography is of value in 
patients with indeterminate mammograms due to its high negative predictive value. 
Therefore, a separate Additional Study, with the same scintigraphic method, 
was conducted on patients with clinical breast lumps with indeterminate 
mammographic lesions. Special emphasis was placed on lesion by lesion comparison 
of each breast lesion detected by clinical examination or scintimammography or both 
with the biopsy results of that particular lesion. 
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CHAPTER ONE 
INTRODUCTION 
1 
Introduction 
1.1. BACKGROUND 
Breast cancer is the most common and probably the most feared malignancy of 
women today. It is the leading cause of cancer related deaths in women in the United 
States after lung cancer, with 46,000 deaths from the disease and 183,400 new breast 
cancer cases reported in 1995. The incidence of breast cancer has been reported to be 
rising at an annual rate of3% in US [l]. In South Africa during 1992, 4084 new breast 
cancer cases were recorded by the National Cancer Registry. The overall lifetime risk of 
developing cancer in the female population in South A:fica is 1 in 31 [2]. 
The primary purpose of screening women for breast cancer is to diagnose breast 
cancer at an early stage and thus reduce mortality. Traditionally, clinical breast 
examination, mammography and ultrasonography have been the mainstay of breast cancer 
detection. Mammography has been shown to have certain limitations [3-6]. Ultrasono-
graphy results in improved specificity when used in combination with mammography and 
is used in most breast centres to direct patient management. The sensitivity and specificity 
of ultrasound is variable and depends upon multiple factors. However, newer transducers 
seem to be more sensitive [7]. At the same time, newer imaging modalities, including 
several nuclear imaging techniques, have become important role players in breast cancer 
detection [8]. 
Scintimammography (SMM) is a relatively recent development in clinical nuclear 
medicine. Thallium 201 (Tl-201) and recently Technetium-99m methoxyisobutylisonitrile 
(Tc-99m MIBI) have been suggested as radiopharmaceuticals with a great deal of promise 
in imaging breast cancer. Recent medical literature contains several reports regarding the 
efficacy of these agents [9-21]. Tc-99m MIBI has been at the forefront ofradiopharma-
ceuticals used for breast cancer evaluation. The United States Food and Drug Administra-
tion has recently approved the clinical use ofTc-99m MIBI for breast imaging as it has 
been found to be a potentially important radiopharmaceutical for the evaluation of primary 
breast cancer. 
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1.2. AIMS 
The aims of the study were: 
Firstly, to determine ifTc-99m MIBI scintimammography differentiates benign 
from malignant breast lesions and secondly, to compare the sensitivity and specificity of 
Tc-99m MIBI scintimammography with that of mammography in the detection of primary 
breast cancer. 
1.3. SCOPE AND LIMITATIONS OF RESEARCH 
The results of numerous recent trials, using Tc-99m MIBI, have shown high 
sensitivity, specificity and predictive values for the detection of palpable breast cancer 
[22]. The reasons for this study were to validate the results of others with respect to 
sensitivity and specificity, using an optimal imaging method. Therefore, for the first time 
at our institution, we have tested the value of this relatively new non-invasive diagnostic 
modality for the detection of breast cancer, in addition to already well established 
procedures like x-ray mammography and biopsy. 
1.4. STRUCTURE OF THE THESIS 
The next chapter (2) covers the relevent literature review pertinent to the diagnosis 
of breast cancer. The role of mammography, its limitations and those of nuclear medicine 
imaging, with special emphasis on Tc-99m MIBI in the diagnosis of breast cancer, have 
been reviewed. 
Chapter 3 deals with the methodology, and describes the sample selection criteria, 
method of fractionating sestamibi including its quality control and the actual 
scintimammography (SMM) imaging procedure. 
Chapter 4 describes the results of SMM, mammography and biopsy findings and 
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their comparative analysis. 
Chapter 5 contains an additional study, conducted on patients with clinically 
palpable breast lumps and with indeterminate mammography findings, in order to 
determine the value ofTc-99m MIBI SMM in diagnosing breast cancer in those patients. 
Chapter 6 includes discussion on the findings of the research and relating them to 
published studies and reporting both the importance and the limitations of the research. 
Chapter 7 describes the conclusions drawn from this study. Also included are the 
recommendations arising from the research. 
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5 
Literature Review 
In this chapter, the literature pertinent to the diagnosis of breast cancer in general 
and the use of nuclear medicine in particular, is reviewed. Special emphasis is laid on the 
use of Tc-99m MIBI, the reagent of interest in the present study. 
2.1. IMPORTANCE OF BREAST CARCINOMA AND ITS DIAGNOSIS 
Breast cancer is the leading cause of death among women between the ages of 40 
and 55 years. The best line of defence against it is early detection. The three early 
detection methods currently used are breast-self examination, clinical breast examination 
and screening mammography. As 9 out of 10 breast cancers can be discovered by women 
themselves, regular and correct breast self-examination must be taught to all women, 
regarding what symptoms and signs to look for and which changes are significant enough 
to merit further examination. 
The doctor may detect a breast problem in a patient with a specific symptom or in 
an asymptomatic patient, as part of a routine medical examination. The earlier the doctor 
is presented with a problem, the sooner treatment can be started. A suspicious feature 
detected on clinical examination will require further investigation and treatment. The 
detection of early breast tumours on screening mammography can significantly contribute 
to the early diagnosis of breast cancer. Neither breast examination nor mammography, 
however, can accurately differentiate breast cancer from the myriad of benign breast 
abnormalities. 
The diagnosis of breast cancer in patients presenting with breast masses is difficult 
when using non-invasive techniques because of their limitations in distinguishing between 
cancerous and non-cancerous lesions. This causes a great reliance on invasive procedures 
such as biopsy for confirming the nature of a breast lesion. Thus thousands of women are 
subjected to a potentially unnecessary biopsy procedure with associated risk, discomfort 
and expense. According to Kunni [23 ], breast biopsy results are negative for breast cancer 
in 68-87% of women, varying from one institution to another. Therefore, it has been 
suggested that a better diagnostic imaging tool is needed that can reduce the number of 
unnecessary biopsies [24] . 
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2.2. ROLE OF MAMMOGRAPHY IN THE DIAGNOSIS OF BREAST 
CARCINOMA AND ITS LIMITATIONS 
Athough mammography is used routinely and is considered as a non-invasive 
diagnostic tool of high standard, it is actually of limited value in the evaluation of 
clinically evident breast abnormalities as it can potentially "overdiagnose" the number of 
breast cancers. Mammography depends on the differential attenuation ofx-rays passing 
through compressed breast tissue. Breast malignancies are detected due to spiculation and 
calcifications within or around neoplasms or the increased density of the neoplastic tissue 
relative to adjacent normal breast tissue. According to Sickles [ 6], calcifications may 
sometimes be the only evidence for malignancy within the breast. However, many benign 
conditions also result in calcifications, which will result in false positive mammograms. 
Kopans [25] has suggested that the primary value of mammography is the earlier 
detection of breast cancer through the screening of asymptomatic women. However, there 
is value in mammography for symptomatic women, but it should not be overestimated. He 
further states that mammography is used routinely to assess an individual who has a lump, 
thickening, discharge or other sign or symptom that might indicate a possible malignancy. 
Mann et al. [26] have reported that in women with fatty breasts the mammographic 
interpretation is known to be very accurate but it has certain limitations, particularly in 
young women with dense breasts, because radiographically dense glandular breast tissue 
may obscure an underlying tumour. 
Some mammographic screening studies have shown that early detection of breast 
cancer allows a 30% reduction in mortality in patients older than 50 years [27-30]. The 
screening mammography method has the potential to detect lesions well before they are 
palpable. The threshold for screening mammography to detect a breast lesion may be as 
low as 2 mm [31]. Shapiro [32] has reported that mammography with current film screen 
technique is sensitive in detecting breast cancer. According to Lannin et al. [33], however, 
there are still significant limitations to the use of mammography in the detection of breast 
cancer, and these limitations persist in spite of technical improvements that facilitate 
diagnosis, especially in women with dense breasts. Kopans [25] has suggested that, as 
mammography fails to demonstrate between 5% and 15% of cancers, it cannot be relied on 
to exclude a malignancy. 
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The purpose of breast imaging is the detection of lesions and differentiation of 
benign from malignant lesions. According to Hermann and Winsberg, ''Each new modality 
must be compared to x-ray mammography to determine whether it can supplement or 
replace mammography in detecting and characterising breast abnormalities. If an imaging 
modality complements plain mammography in detection of lesions or differentiation of 
benign from malignant lesions, then it should be used" [34]. Several recent articles have 
emphasised the role of nuclear medicine techniques in the detection of breast carcinoma 
[7,8,22]. 
2.3. ROLE OF NUCLEAR MEDICINE IMAGING IN THE DIAGNOSIS OF 
BREAST CANCER 
Nuclear medicine techniques rely on biological and physiological characteristics of 
tumours and have been used to evaluate breast cancer. 
2.3.1. Radiopharmaceuticals 
A wide variety of radiopaharmaceuticals have been used for breast imaging.[22] . 
These include nonspecific tumour imaging agents like thallium-201 (Tl-201) [9,35-37] and 
technetium-99m (Tc-99m) labelled agents, which include methoxyisobutylisonitrile 
(MIBI) [10,12-21,38,40-42] and tetrofosmin [42-46], the bone imaging agent Tc-99m 
methylene diphosphonate (MDP) [20,47], and specific agents such as indium labelled (In-
111) somatostatin analogs [48-50] and monoclonal antibodies. 
Breast tumour scintigraphy was first performed with thallium chloride (Tl-201) 
[ 51] but thallium has largely been replaced by technetium-99m labelled MIBI because of 
its superior imaging characteristics. Originally developed as a myocardial imaging agent, 
Tc-99m MIBI has been found to concentrate in a number of different tumours [52,53]. 
The first use ofTc-99m MIBI in tumour imaging was reported by Muller et al. [54]. 
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2.4. TECHNETIUM-99m HEXAKIS-2-METHOXY-2-ISOBUTYLISONITRILE 
(Tc-99m SESTAMIBI): A VALID BREAST TUMOUR IMAGING AGENT 
2.4.1. Structure of Sestamibi 
CH3 I 
R=-CH2 - 1-oCH3 
CH3 
+1 
Tc-99m sestamibi (MIBI) is a positively charged lipophilic complex belonging to a 
new class of Tc-99m labelled isonitrile compounds, formed with technetium in a + 1 
oxidation state [Tc (I)]. The ligand tetra (2-methoxyisobutyl isocyanide) copper (I) 
chloride is synthesized by heating 2-methoxyisobutyl isocyanide with anhydrous cuprous 
chloride in anhydrous ethanol at 90°C for 1 hour. The compound is purified and prepared 
in a kit form for labelling with Tc-99m pertechnetate. After labeling the six monodentate 
methoxyisobutyl isocyanide (MIBI) ligands are symmetrically attached to the central 
Tc-99m atom [55]. 
2.4.2. Clinical role of Sestamibi 
Tc-99m MIBI has been effectively used in tumour imaging of patients with lung 
cancer [13,56], recurrent brain gliomas [57], bone tumours [58], carcinoma of the thyroid 
gland [59], parathyroid adenomas [60], and more recently, breast carcinoma [10,12,14,21]. 
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In published research series, sestamibi breast imaging has demonstrated high 
sensitivity and specificity in differentiating benign from malignant breast lesions when 
compared to histopathological results. Several studies demonstrate overall sensitivity of 
84%-96% for the detection ofbreast carcinoma using Tc-99m MIBI [12,14,16,18,61]. 
2.4.3. Experimental Evidence 
Most breast cancers have increased blood flow and many tumours induce 
neovascularity strictly to facilitate tumour growth. Scopinaro et al. [62] have shown a 
close relationship between neoangiogenesis and Tc-99m MIBI uptake. Their study 
suggested that Tc-99m MIBI is a marker of breast cancer invasiveness: its uptake is 
related to angiogenesis and; possibly, to oxidative metabolism of the tumour. 
Experimental studies on cultured normal cells and carcinoma lines using 
Tc-99m MIBI have shown that neoplastic cells have a metabolic rate of 4-10 times that of 
normal cells [11]. These experimental studies with cultured cells emphasize the role Tc-
99m MIBI can play for in vivo tumour imaging in humans. The experimental results of De 
Jong et al. [44] showed that, among the Tc-99m labelled compounds tested, Tc-99m MIBI 
has the highest cellular uptake in 60 minutes, in both normal and human breast tumour 
cells, theoretically making it the most suitable compound for imaging. Delmon-Moigeon 
et al. in 1990 demonstrated in their experiments, uptake ofTc-99m MIBI in nine tumour 
cell lines [63]. Preliminary reports have suggested in vivo localization ofMIBI in primary 
cancers and metastatic deposits from thyroid, lung and bronchial carcinoma [ 64]. 
Stimulation of metabolism by some growth factors [65] or changes in neoplastic plasma 
membranes may also play a role [63 ,66]. 
2.4.4. Advantages of Tc-99m MIBI over Tl-201 
Tc-99m MIBI has some properties similar to those ofTl-201 chloride (e.g. 
myocardial accumulation) as well as some dissimilar characteristics (notably lack of 
redistribution). It has been successfully evaluated for myocardial imaging [67,68]. 
Labelling with Tc-99m has several advantages over Tl-201 . These advantages are related 
to its continuous availability for use, freedom in patient scheduling, smaller radiation dose 
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to the patient, larger injected dose and better physical characteristics for both dynamic, 
static and tomographic studies [56]. 
2.4.5. Mechanism of Uptake of Tc-99m MIBI 
Many studies have shown that Tc-99m MIBI is often, but not always, taken up by 
breast cancer cells [10,14,18,41]. Crane et al. [69] recently performed an experimental 
study using Tc-99m MIBI imaging in the c-neu Onco Mouse TM (transgenic mouse that 
spontaneously develops mammary tumours). Results showed that tumour retention of 
Tc-99m MIBI was highest at the periphery of the tumour, while the centre of the tumour 
( often acellular and filled with blood and necrotic debris) showed less retention. These 
data support the use of Tc-99m MIBI as a marker of active cellular tumour tissue. Recent 
data suggest that 90% of the Tc-99m MIBI activity is concentrated in the mitochondria 
[70]. The exact mechanism of uptake ofTc-99m MIBI by tumour cells is not yet clearly 
understood. It has been shown that Tc-99m MIBI is taken up by mitochondria using some 
form of active transport, but is passively transferred across the cell membrane [ 18].lt 
accumulates within the mitochondria and cytoplasm of cells on the basis of trans-
membrane electrical potentials [71] . 
2.4.6. Pharmacokinetics of Tc-99m MIBI 
After intravenous injection at rest, the highest Tc-99m MIBI concentration is found 
in the gall bladder and liver, followed by the heart, spleen and lungs. As hepatic activity 
decreases in the first hour because of excretion via the biliary tract, maximum 
accumulation occurs in the gall bladder at 60 minutes [67]. Twenty percent of the injected 
dose is cleared through renal elimination in 24 hours. The agent is excreted without any 
evidence of metabolism [72]. 
2.4. 7. Dosimetry 
Organ dosimetry ofTc-99m MIBI demonstrates that a dose of740 l\IBq (20 mCi) 
delivers 0.03 Gy (3 rads) to the large intestine, which is the predominant target organ. The 
whole body dose is 0.003 Gy (0.3 rad) [67]. 
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2.5. FACTORS AFFECTING UPTAKE OF TECHNETIUM-99m MIBI 
There are many factors which can affect the uptake ofTc-99m MIBI in SMM 
imaging and therefore influence the detection. The nature, size and location of the breast 
lesion are among the important factors. These effects are discussed in detail in Chapter 6. 
Chemotherapy and/or radiotherapy prior to surgery can also have an effect. This factor did 
not play an important role in the present study because coincidentally none of the patients 
we selected had had chemo and/or radiotherapy prior to surgery. Therefore this is not 
discussed in Chapter 6, but a brief review of the pertinent literature follows here. 
2.5.1. Effects of Chemotherapy and Radiotherapy 
It is assumed that as breast conserving surgery continues to become more prevalent 
[73], the ability ofMIBI breast imaging to noninvasively investigate the primary breast cancer 
will become very important. Chemotherapy administered prior to surgery allows breast 
conservation in a far greater number of women and may improve survival from breast cancer 
even in advanced stages [74]. Mankoff et al. [75] performed Tc-99m MIBI SMM in 14 
patients with locally advanced breast cancers, who underwent chemotherapy before surgery. 
The SMM was done before and after chemotherapy and then followed by surgery. These 
authors suggested that this reduced uptake ofTc-99m MIBI may have been related to 
pleiotropic (multiple) drug resistance (MOR). 
According to Kabasakal et al. , multiple drug resistance (MOR) is a problematic form 
of resistance in which tumour cells that become refractory to chemotherapy develop cross-
resistance to a variety of other agents [76]. This resistance to a broad range of structurally 
unrelated drugs, due to enhanced outward transport of drugs, is mediated by p-glycoprotein 
that is encoded by multiple drug resistance gene (MORI). This specific protein functions as an 
energy-dependent extrusion pump that efficiently transports cationic and lipophilic 
chemotherapeutic agents as well as some toxins, causing decreased accumulation and 
decreased retention of these agents. The same mechanism for the outward transport of all 
drugs was found to be responsible for the rapid efflux ofMIBI from cells resulting in its 
suboptimal intracellular accumulation [77]. 
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Recently, Piwnica-Worms et al. [78] have shown that decreased accumulation ofMIBI 
in MDR cells can be reversed by administration of MDR-modulating agents such as 
verapamil. Varrella et al. [79] and Khalkhali [22] have also reported similar results, which 
suggest that decrease in MIBI uptake after chemotherapy could be used to detect p-
glycoprotein-dependent MDR and so aid in tailoring chemotherapy protocols and developing 
new drugs targeted to inhibit p-glycoprotein expression. 
On the other hand, Cwikla et al. [80] showed that infact reduced uptake ofTc-99m 
MIBI after chemotherapy might be a non-specific change i.e. not related to MDR and 
therefore not predictive of the clinical response to treatment. They demonstrated that the 
reduction in the uptake ofTc-99m MIBI in patients receiving chemotherapy as initial 
treatment, before surgery, was independent of the tumour size. Reduced uptake was seen not 
only in those patients in whom tumour size was reduced but also in patients in whom tumour 
size increased during treatment. This is because the size of the lesion is influenced by other 
factors, such as oedema and inflammatory cell infiltrate. 
Cwikla et al.[80] also suggested that the reduction in uptake of Tc-99m MIBI did not 
bear any relationship to clinical response. The proportion of viable malignant cells present is 
important rather than the size of the lesion. They showed that exposure of the tumour to 
cytotoxic chemotherapy results in reduced uptake ofTc-99m MIBI, and assumed that these 
changes in uptake were due to expression of the MDR-1 gene or interference in the 
mitochondrial uptake ofTc-99m MIBI. 
The effect of radiotherapy on Tc-99m MIBI uptake in tumours was first shown by 
Hassan et al. [56]. They demonstrated reduced MIBI uptake in patients with lung carcinoma 
after radiotherapy (2000 rads). They reported that the mechanism of the radiation effect 
seemed to be related to interference with the binding of MIBI to intracellular protein 
(lysosome protein to which MIBI is attached in a viable cell). Presumably, similar effects 
could be implicated in breast cancer which shows decreased MIBI uptake. 
2.5.2 Technical Aspects to be considered in SMM 
Careful patient positioning is critical to SMM interpretation. Protocols used for 
SMM have included supine, upright and prone imaging [12,20,40]. Diggles and co-
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workers [ 40] described prone dependent-breast imaging, which has several advantages 
over the supine or upright position. The prone position allows relaxation of anterior chest 
muscles, which helps in evaluating deep breast tissue adjacent to the chest wall. This 
position also allows improved separation of breast tissue from liver and myocardium, 
allowing improved lesion detection. 
14 
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3.1. PURPOSE 
As stated in Chapter 1, the objectives of the study were firstly, to determine if Tc-
99m sestamibi (M1BI) scintimammography differentiates benign from malignant breast 
lesions and secondly, to compare the sensitivity and specificity of Tc-99m MIDI 
scintimammography (SMM) with that of mammography in the detection of primary breast 
cancer. 
3.2. SAMPLE SELECTION 
The study population consisted of 51 women between the ages of 3 3 and 81 years 
with a mean age of 50 years. This formal study followed a pilot study on a sample of 11 
patients chosen according to the same criteria (see Appendix A). 
Women selected for this trial were chosen by an experienced surgeon at the Breast 
Clinic at Groote Schuur Hospital, Cape Town and represent patients with clinically 
palpable breast lumps. Some of these selected patients also had a high risk of breast cancer 
and therefore a higher prior probability of the breast lumps being malignant, due to: 
a) A family history of breast cancer; 
b) Previous occurrence of breast cancer; 
c) Previous breast surgery. 
The Combined Breast Clinic (CBC) is held once every week at Groote Schuur 
Hospital in its out-patient department. The concept of CBC is well known in many 
developed countries [81] . In our institution it is jointly run by the multidisciplinary teams of 
breast specialists from departments of Surgery, Radiotherapy, Anatomical Pathology 
(Cytopathology) and Radiology. Only patients with breast diseases are referred to the clinic 
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for screening and follow-up purposes. All patients are seen as out-patients. For patients 
with breast lumps, combined assessment (aspiration cytology and mammography) of 
clinically suspicious breast masses is performed. The patients who need further evaluation 
and treatment are referred to the respective departments. This routine is practised at the 
CBC, firstly to improve efficiency and secondly, as a cost and time saving measure for the 
patient and the hospital. Mammography and Fine Needle Aspiration Biopsy ( FNAB) are 
performed as part of the normal screening process on all patients with clinically palpable 
breast lumps. 
The patients selected for nuclear medicine breast imaging, Scintimammography 
(SMM) , along with routine Mammography and FNAB, usually underwent all these 
investigations on the same day. They always underwent SMM before the FNAB, because 
FNAB is a minor surgical (invasive) procedure and therefore can potentially interfere with 
the results of SMM. All these patients were asked for their informed consent and the 
research was explained to them. 
The FNAB was performed at the Combined Breast Clinic. The mammography and 
SMM scans were done in the Departments of Radiology and Nuclear Medicine respectively. 
The following patients with palpable breast lumps were excluded from selection for 
SMM: 
1. Patients who had undergone any invasive procedure on the involved breast 
during the past month ( e.g biopsy) or had any inflammatory lesion ( e.g. mastitis, 
ulceration), as these may cause false evidence of increased activity in the breast to appear 
on the scan. 
2. Pregnant patients, to avoid any radiation effects on the foetus . 
3. Patients who were physically or mentally handicapped and could not comprehend 
the prerequisites of the scanning procedure or give informed consent. 
As there was no definitive imaging protocol available at the time the trial was 
started, a pilot study was conducted in order to determine an appropriate imaging 
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procedure (see Appendix A). 
3.3. PROCEDURE 
All the patients underwent scintimammography scans using locally produced 
sestamibi (methoxyisobutylisonitrile-Myotek) produced by the Atomic Energy Corporation 
(AEC) of South Africa. 
Each vial contained: 
[Cu(DMJ)4}BF4 
Cysteine 
Sodium dihydrogen citrate 
Mannitol 
Tin dichloride(SnC/2. 2H20) 
(DM 1: one deuterium atom) 
Sestamibi is produced in lypholysedform and not as liquid. 
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3.3.1. Use of Fractionated Sestamibi 
Cost-effective preparation of various Tc-99m radiopharmaceuticals by splitting 
kits has been explored in recent years. Use of fractionated MIBI is economically 
advantageous and may enable many additional patients to be diagnosed [82] . 
In order to make the radiopharmaceutical economically affordable, each vial of 
MIBI was divided into multiple fractions (fractionated) before use. Each sestamibi vial 
was reconstituted with sterile saline, and divided into 10 fractions. Quality control was 
performed on each fractionated dose to ensure the purity and efficacy of the product. 
3.3.2. Fractionation Procedure 
Items required: 
1. A vial of sestamibi from the refrigerator which was allowed to equilibrate to 
reach room temperature. 
2. Ten "elu" / 10ml vials from the hot laboratory, to store the fractionated sestamibi. 
These vials were labelled with the radiopharmaceutical name, lot number and 
date of fractionation. 
3. A 10ml vial of nitrogen-purged saline from the hot laboratory. This was used to 
reconstitute the sestamibi. 
Method 
Fractionation was performed in a Laminar Flow Cabinet (LFC) as the 
fractionated sestamibi might be stored for extended periods and it is essential to maintain 
sterility. 
1. The LFC was switched on and the stainless steel tray wiped with alcohol. 
2. Anything not removed from sterile packaging was sprayed with alcohol before it 
was introduced into the LFC. 
3. The vials were purged with nitrogen, in order to provide an oxygen-free storage 
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units were attached to the green tubing connected to the nitrogen cylinder and 21-
gauge needles to the other end of the filters. All the tubing was wiped with alcohol 
before being put into the LFC. 
4. 5ml of nitrogen-purged saline was withdrawn into a 5ml syringe using a 
21-gauge needle. It was necessary to ensure that there were no air bubbles in the 
syringe, as any air introduced into the sestamibi will adversely affect the labelling 
efficiency. 
5. 5 ml of saline was added to the sestamibi vial, an equal amount of air being 
withdrawn to equalise the pressure. The vial was shaken gently several times. 
6. The entire contents of the vial of reconstituted sestamibi vial were withdrawn into a 
5ml syringe, fitted with a 26-gauge needle. Again all air bubbles were eliminated. 
7. 0.5ml of the reconstituted sestamibi was introduced into each elu vial, with 
exclusion of air. 
8. All elu vials were purged with nitrogen in the following manner: 
A small 26-gauge needle was inserted into the elu vial. The 21gauge needle 
attached to the filter was then pushed into the elu vial, and the nitrogen cylinder was 
turned on to a pressure of 60kPa. After one minute of purging both needles were 
removed simultaneously. 
9. The reconstituted sestamibi was stored in the freezer compartment of a refrigerator 
at -4 to -8°C. 
In order to compensate for oxidation of tin during the storage of sestamibi, 
additional tin was added to the fractionated sestamibi. The tin was obtained from invivo 
Red Blood Cell Labelling Agent, manufactured by AEC of South Africa. Each vial of 
invivo Red Blood Cell Labelling Agent contains 2504g of tin. 
When required, the individual dose was thawed at room temperature and mixed 
with Tc-99m pertechnetate. 
20 
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Each dose was prepared as follows: 
1. A vial of fractionated sestamibi was removed from the freezer and allowed to stand 
on a bench top to thaw and reach room temperature (approx. 5 minutes). 
2. A vial of invivo Red Blood Cell Labelling Agent was diluted with 5ml of normal 
saline. Then 0.1ml of the diluted solution (containing 50.08µg of tin) was added to 
the thawed sestamibi as described, followed by approximately 1000 MBq ofTc-
99m pertechnetate. 
3. The vial was then placed in boiling water for 10 minutes after which it was cooled 
in cold water for 2 minutes. 
3.3.3. Quality Control of Fractionated Tc-99m Sestamibi 
Each reconstituted dose was tested, before use, to ensure that the labelling 
efficiency was satisfactory. Miniaturized rapid ascending paper radiochromatography 
technique, developed by Owunwanne et al. [83 ], was performed as illustrated in Figure 3 .1. 
21 
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Mobile Phase: Ethyl acetate 
Stationary Phase: Schleicher & Schull paper No. 2040 A 
TOP 
-----------------------------~---+~Solvent front 
7.5 cm 
2cm 
-----------------------------~ 
~ Origin 
1.5 cm 
BOTTOM 
Figure 3.1. Illustrating the dimensions of the Scheicher & Schiill paper and the levels of 
solvent movement. 
Method: 
1. Ethyl acetate was added to a 100 ml beaker to a depth of approximately 1 cm. 
2. The upper end of the paper strip (10 x 2cm) was pierced with an orange needle. 
3. The strip was placed on 2 supports. 
4. With a 1ml syringe, a small amount of the radiopharmaceutical was spotted at the 
origin. A copper wire holder was threaded through the hole in the strip and the strip 
was suspended in the beaker containing the ethyl acetate. The bottom of the strip 
was immersed in the ethyl acetate but its level was well below the 
radiopharmaceutical spot. 
22 
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5. The chromatogram was developed until the solvent front reached the upper line 
(approximately 7 minutes). 
6. When the solvent front reached the upper line (1cm from the top of the paper) the 
strip was removed and dried. The dried strip was then fixed to a glass plate. 
7. The protocol QC Phann, available on all GE cameras, was used for acquisition and 
analysis of the radiochromatogram. A parallel hole collimator was used. 
8. The strip was positioned on the collimator in such a way that the origin was on the 
left side of the image. This was checked with a radioactive source. 
9. The following RF (mobility relative to front) values apply for MIBI: 
Impurities: RF: 0. 0 
Labelled product: RF: 1. 0 
10. The data analysis may be done automatically or manually. The automatic analysis 
will work correctly if MIBI is the most intense dot on the image. If it is not, the 
manual analysis should be used. 
The radiochemical purity of the Tc-99m labelled sestamibi, injected into the 
patients, was 89% or more for all but one sample in which labelling efficiency was 
80% (see Figure 3.2). 
3.3.4. Scintimammography Procedure 
The procedure used for scintimammography (SMM) is described below: 
A gamma camera (GE 400 AC Starcam) equipped with a low-energy, high-
resolution collimator was used for imaging. A brief description of the gamma camera and 
imaging procedure was given to each patient before scanning. 
Privacy was provided in the camera room by putting a curtain screen in front of the 
entrance and by restricting entry strictly to necessary staff members only (the researcher 
and radiographer). The patient was requested to undress down to the waist and was 
provided with a surgical gown to wear with the opening in front~ the gown was 
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kept loose so that proper prone positioning could be achieved. Both breasts an
d axillae 
were examined for palpable lesions before the tracer was injected. 
The patient's breast was divided into four anatomical quadrants and the nipple
 used 
as an anatomical landmark in order to describe the position of the breast lesion
. We 
developed an adhesive radioactive marker to mark the position of the nipple. T
his was 
based on an ECG chest electrode. A minute amount ofTc-99m pertechnetate w
as spotted 
on a small cotton plug, which was then carefully sealed with cellophane tape an
d securely 
stuck to the metallic tip of the electrode. The adhesive side of the electrode wa
s used to 
stick the marker on the nipple of the breast. 
An intravenous dose of740 Mbq ofTc-99m MIBI was given in the arm 
contralateral to the affected side. In patients who had clinically bilateral breast
 lesions, the 
injection was given in either of the arms.The breast on the side of the injection was scanned 
last. 
3.3.4.1. Patient and camera position 
Planar views of both breasts were acquired in the following projections and 
sequence: 
1. Lateral view. 
2. Posterior oblique view at 25 degrees 
3. Anterior chest/axillary view 
The affected breast was imaged first. 
The patient lay in the prone position for lateral and posterior oblique views in 
exactly the same way as in the pilot study (Appendix A). For the lateral view, the surface 
of the detector was positioned vertically parallel and close to the breast. For th
e posterior 
oblique view, the patient remained in the same position and the detector was ti
lted to 25°, 
keeping the breast in the centre of the field of view. The ipsilateral axilla and a
djacent 
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anterior chest wall were included in the field of view to detect any lymph node involvement 
and deep-seated lesions in the breast or chest wall, respectively. 
Just before each image acquisition was started, the nipple was marked by using the 
radioactive marker described above. After the marker had been stuck over the nipple, its 
position was indicated on the screen with a"+", using the marking facility of the gamma 
camera. The marker was removed from the nipple before the acquisition was started. 
For the anterior chest/axillary view, the patient lay in a supine position in the same 
way as in the pilot study (Appendix A). The detector was positioned above the anterior 
chest, parallel and close to the breast. The entire breast and axilla were included in the field 
of view. 
Other acquisition parameters included an image zoom of factor 2 for lateral and 
posterior oblique views, in order to magnify the breast image and to exclude heart and liver 
activity. No image magnification was used for the anterior chest I axillary view. Images 
were acquired in a 256x256 matrix covering an area of 400 mm in diameter when the zoom 
factor was 1. The photopeak was centered at 140 ke V with a 10% symmetric energy 
window. 
Only one set of images was acquired on each breast. Imaging started 5 minutes after 
the injection of the tracer. The affected breast was always imaged first. The injection site 
was always kept out of the field of view. All images were acquired for a preset time of 5 
minutes. The patient was allowed to rest for a few minutes after the images of the first 
breast were completed. 
After acquisition had been completed, the study was transferred to another 
computer terminal to make hard copies of all the images. All images were interpreted 
visually both on the computer screen and on the hard copies, to detect any abnormal 
increased activity of the tracer in the breast or axilla. The objective assessment was 
performed by semiquantitative analysis using target to background (TIB) ratio, as described 
below. 
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The intensity of MIBI uptake within the visually detected breast lesion was 
evaluated by determining the TIE ratio. Either the lateral or posterior oblique view of the 
breast was selected to draw the region of interest, depending upon which view better 
illustrated the lesion. 
The total counts obtained in each view were recorded. In addition on lateral view, 
irregular region of interest were drawn around each breast, excluding the chest wall. The 
total counts in each irregular ROI and area in pixels, were used to calculate counts per pixel 
for each breast. These recorded data can be seen in Table 5 of Appendix B. 
A square region of interest was drawn within the outline of the breast lesion. 
Another region of the same dimensions was drawn over the apparently normal breast tissue 
of the same breast. The background region was drawn at a variable distance, ranging from 
0.5 to 1.5 cm from the target region, in different patients. In breasts with more than one 
target lesion, a common background region was drawn in the same breast, at approximately 
the same distance from the target regions. TIE ratios were the ratios of the total counts for 
each region of interest. 
The TIB ratio was used as a quantitative measure to determine whether it could 
help to distinguish between true malignant and benign breast lesions. 
3.3.5. Scan Interpretation 
From visual assessment of the scintimammographic scans the breast lesions were 
classified as positive, negative or indeterminate. The following criteria were used: 
POSITIVE: A clearly defined area of increased uptake 
with an intensity greater than the normal 
surrounding breast tissue. 
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INDETERMINATE: 
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No focal increased uptake in the breast. 
An ill-defined area of low-grade increased 
uptake which is unclassifiable as benign or 
malignant; as there is increased uptake, it 
cannot not be termed normal, but the 
uptake is not intense or well enough 
defined to be classified as malignant. 
All studies were evaluated by the researcher and another experienced nuclear 
medicine physician. A third observer, another nuclear medicine physician, was referred to in 
cases of disagreement. 
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4.1. CLINICAL EXAMINATION 
A total of 54 palpable breast lumps in 53 breasts of 51 patients were found on 
clinical examination. Twenty four patients presented with solitary breast lumps in the
ir right 
breast and 24 patients with lumps in their left breast. Another patient had two palpab
le 
lumps in her left breast, while 2 more patients presented with one lump in each breast
. 
Three of the patients presented with possible tumour recurrence after surgery and 
radio and chemotherapy. Ten had a positive family history of breast cancer. 
Six were nulliparous and 3 of these were among those with a positive family history 
of breast cancer. 
The distribution of 54 breast lesions palpated on clinical examination are shown in 
Table 4.1. 
Patient details are enlisted in Table 2 in Appendix B. 
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Table 4.1: Number And Distribution Of Lesions In Each Breast On Clinical 
Examination. 
RIGHT BREAST LESIONS 
Upper Outer Quadrant: 8 
Upper Inner Quadrant: 7 
Lower Outer Quadrant: 7 
Lower Inner Quadrant: 1 
Other (periareolar): 3 
TOTAL 26 
LEFT BREAST: LESIONS 
Upper Outer Quadrant 16 
Upper Inner Quadrant: 2 
Lower Outer Quadrant: 8 
Lower Inner Quadrant: 1 
Other (periareolar): 1 
TOTAL 28 
31 
Results 
Results 
4.2. BIOPSY RESULTS 
All 51 patients had biopsies done. These include 54 palpable lesions in 53 breasts. 
Biopsies were also performed on 3 clinically impalpable lesions. Of these, 2 were situated 
close to the palpable lesions, seen on mammography and SMM; and another lesion was 
seen only on mammography, in a clinically normal breast. These make a total of 57 
lesions in 54 breasts which were biopsied (54 palpable and 3 impalpable). Further 2 
impalpable lesions in one of these breasts were seen only on SMM and were not biopsied. 
Three of the patients with palpable lumps had clinical suspicion of tumour 
recurrence after treatment. Two of these showed normal breast tissue with some sclerosis 
on histological examination. One patient had a recurrent infiltrating ductal carcinoma at 
the site of previous cancer. 
In the 10 patients with positive family history of breast cancer, 4 were found to 
have malignant lesions while the other 6 patients had benign breast lesions. Two of the 6 
nulliparous patients had malignant breast lesions, while 4 had benign breast lesions. Two 
patients with mammographically dense breasts were found to have fibroadenomas on 
histology. 
In total, there were 22 malignant lesions in 21 breasts of 21 patients, including 2 
patients who had bilateral breast masses, with malignant lesions in one and benign lesions 
in the other breast. One of these patients (patient 25) had a ductal carcinoma in her left and 
fibrocystic disease in her right breast, confirmed on histology. The other patient (patient 
44) had clinically palpable lumps in the left breast showed bilateral involvement on 
mammography, with 2 cystic lesions in her left and a small Ix I cm solid lesion, an 
adenocarcinoma in situ, in her right breast which was clinically impalpable. 
A total of 35 benign lesions in 33 breasts of32 patients were biopsied. These 
included a patient with bilateral breast lesions (bilateral fibroadipose tissue masses) and 4 
patients with biopsy confirmed normal breast tissue. The histopathological results are 
listed in Table 4.2. 
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Table 4. 2: Histopathological Results of 57 lesions in 54 breasts. 
HISTOPATHOLOGICAL FINDINGS LESIONS BREASTS 
Malignant Tumours : 
Infiltrative Duct Ca. 15 15 
Lobular Ca. 4 3 
Colloid Ca. 1 1 
Adeno Ca. 1 1 
Phylloides Tumour 1 I 
Benign Tumours : 
Fibroadenoma 7 7 
Lipoma I I 
Other Benign Lesions : 
Fibrocystic Disease 5 4 
Fat Necrosis 4 4 
Fibrosis/Sclerosis I 1 
Inflammatory Lesions 5 5 
Cyst 5 4 
Fibroadipose Tissue 3 3 
Normal Adipose tissue 4 4 
Total 57 54 
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4.3. MAMMOGRAPHY RESULTS 
A total of 57 lesions in 54 breasts of 51 patients were noted on mammography. 
Of the 3 patients referred with clinically palpable breast masses for suspected 
tumour recurrence, one was found to have a recurrent infiltrating ductal carcinoma on 
histology, but the mammography showed no definite mass besides scarring (false negative 
mamogram). In the other 2 patients, one had features of benign pathology, while the other 
had a normal mammogram. Both these results corresponded with the biopsy results. 
Table 4.3: Summary of Histopathological and Mammography Results. 
HISTOLOGY 
Malignant Benign 
Positive 16 0 
MAMMO Negative 4 32 
Indeterminate 2 3 
Of the 22 malignant lesions in 21 breasts, mammography was positive in 16 
lesions in 16 breasts (including 3 patients with positive family history of breast cancer) 
while 4 malignant lesions in 3 breasts showed mammographic features of benign 
pathology (including a nulliparous woman with positive family history of breast cancer). 
Two breasts had solitary lesions with indeterminate mammography results. 
Thirty two benign breasts lesions (including lesions with normal breast tissue) in 
30 breasts showed concordant results on mammography, while 3 lesions in 3 breasts 
showed indeterminate mammographic findings. There were no false positives in this 
category. 
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Also included among these patients was a case (patient 44) in whom 
mammography detected 
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a small spiculated mass with microcalcification, consistent with malignancy, in the 
clinically normal breast during the routine investigation. Excision biopsy showed a lxl 
cm solid lesion with a central focus of invasion approximately 2 mm in diameter. 
Histology results confirmed an apocrine tumour (adenocarcinoma) in situ. It was clinically 
nonpalpable. 
Of the 35 benign breast lesions in 33 breasts, mammography was negative in 32 
breasts lesions including 4 lesions with normal tissue, while 3 breast lesions showed 
indeterminate mammographic features including a nulliparous patient. 
There were 20 patients with mammographically dense breasts. Of these, 3 had 
indeterminate mammographic masses (2 had fibroadenomas and one had invasive ductal 
carcinoma). Three patients with malignant breast lesions (phylloides tumour, infiltrating 
ductal and lobular carcinomas) demonstrated mammographic features suggestive of 
benign pathology (false negative mammograms). The rest of 5 patients with malignant and 
9 with benign breast lesions showed congruent mammographic results. 
4.4. TECHNETIUM-99M MIBI SCINTIMAMMOGRAPHY RESULTS 
All 51 patients had Sl\1M scans. 
Out of a total of 59 lesions in 54 breasts, abnormal increased MIBI uptake was 
noted in 41 lesions in 3 7 breasts. Of these 41 lesions, 28 were regarded as positive and 13 
as indeterminate on Sl\1M. This also includes a patient in whom further 2 lesions were 
detected in one breast on Sl\1M. Rest of the 18 lesions did not show abnormal MIBI 
uptake and were regarded as negative on Sl\1M. 
Table 4.4 shows the number and distribution of lesions in each breast as detected 
on Sl\1M. 
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Table 4.4 Total Number Of Lesions And Their Distribution In Each Breast Quadrant as 
Detected on Tc-99m MIBI Scintimammography. 
RIGHT BREAST LESIONS 
Upper Outer Quadrant 6 
Upper Inner Quadrant 7 
Lower Outer Quadrant 4 
Lower Inner Quadrant 1 
Other (retroareolar) 1 
TOTAL 19 
LEFT BREAST: LESIONS 
Upper Outer Quadrant 9 
Upper Inner Quadrant: 3 
Lower Outer Quadrant: 6 
Lower Inner Quadrant: 4 
Other: 0 
TOTAL 22 
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Of the 3 patients referred with clinically palpable breast masses for suspected 
tumour recurrence, one had a recurrent infiltrating ductal carcinoma and the other 2 had 
benign pathology. All these patients showed negative SMM scans. 
The results are illustrated in Table 4.5. 
Table 4.5: Summary o/Histopathological and Tc-99m MIBI Scintimammography 
Results. 
HISTOLOGY 
Malignant Benign 
Positive 17 9 
Negative 2 16 
Indeterminate 3 10 
Of the 22 histologically confirmed malignant lesions in 21 breasts, 17 lesions 
showed true positive MIBI uptake, 2 lesions showed negative MIBI uptake and 3 lesions 
in 2 breasts showed indeterminate SMM result. 
From a total of 35 benign lesions in 33 breasts, 16 lesions showed negative SMM 
results i.e no MIBI uptake. Nine lesions showed positive MIBI uptake. In one of these 
patients (patient 24) further 2 lesions were detected in one breast on SMM which were not 
biopsied as they were clinically impalpable and not seen mammographically. Ten lesions 
in 9 breasts showed indeterminate SMM features. This includes a patient (patient 58) who 
showed a single fibrocystic lesion in a breast on histology but SMM showed 2 separate 
lesions (one scintimammographically positive i.e false positive and the other 
indeterminate). 
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Details of scintigraphic findings for each pathological diagnosis are given in 
Table 4.6. 
Examples of typical cases with breast lesions as seen on SMM are shown in 
Figures 4.1 , 4.2 and 4.3 in the following pages. 
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Table 4. 6. Scintigraphic Findings Co"elating With Histopathological Results 
Histological Number of Tc99m MIBI Uptake 
Dia~nosis Lesions Positive Ne2ative Indeterminate 
Infiltrative Duct 15 14 1 0 
Ca 
Invasive Lobular 4 2 0 2 
Ca (3breasts) 
Colloid Ca 1 1 0 0 
Adeno Ca 1 0 1 0 
Phylloides Tumour 1 0 0 1 
Fibroadenoma 7 4 3 0 
Lipoma 1 0 0 1 
Fibrocystic Disease 5 3 0 2 
(4 breasts) 
Fat Necrosis 4 0 2 2 
Fibrosis/Sclerosis 1 1 0 0 
Inflammatory 5 3 0 4 
Lesions* (5 breasts) 
Breast Cyst 5 0 5 0 
(4 breasts) 
Fibroadipose 3 0 2 1 
Tissue 
Normal Adipose 4 0 4 0 
Tissue 
* Only 5 lesions in 5 breasts with inflammatory changes were biopsied, whereas SMM 
showed 7 lesions in 5 breasts. 
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Figure 4.1. Normal scintimammogram. Prone left and right lateral vie
ws show 
normal Tc-99m MIBI breast uptake 
Figure 4.2. Ex.amp/es of true-positive Tc-99m SMM (prone lateral views).
 
(i) shows a well defined rounded mass with central necrosis and metastati
c lymph node 
involvement (a"ow). Histology confirmed an infiltrative ductal ca. 
(ii) shows intense focal uptake in a patient with palpable breast lump. Co
nirmed to be 
invasive ductal ca on histology. 
(i) (ii) 
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Figure4.3. 
(i) Examples of false-positive Tc-99m MIBI SMM. A, Fibroadenoma. B, Fibrosis. 
A B 
(ii) An Indeterminate Tc-99m MIBI SMM. A Phylloides tumour (a"ow) 
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4.5. SEMIQUANTITATIVE ANALYSIS 
Malignant breast lesions usually showed higher T/B ratios as compared to benign 
breast lesions as shown in Figures 4.4 (a) and (b). 
Our results showed low sensitivity (66.6%) and specificity (65.5%) for T/B ratio of 
2.0 in differentiating between benign from malignant breast lesions. As the T/B ratio 
increased to 3.0, a steep drop in the sensitivity (33%) and dramatic rise in specificity 
(100%) was noted. (see Figure 4.5). 
Figures 4.6 (a) and (b) show the proportion of benign to malignant lesions with 
increasing T /B ratios. 
Total counts obtained in each view during 5 minutes images, total counts obtained 
in the irregular ROI for each breast in lateral view and area in pixels of these ROI to 
determine counts per pixels for each breast~ and total counts in target and background 
regions and area in pixels, were recorded in Table 5 of Appendix B. 
Figure 4.7 a and b show the relationship between counts per pixel in right and left 
breasts with values ofT/B ratio calculated in the breast. These figures show that there is 
no linear relationship between counts per pixel in a breast and the T/B ratio. 
Figure 4.8 shows distribution of the counts per pixel (in the lateral view) of right 
versus left breast. The points that lie further from the diagonal line show more counts per 
pixel in that breast and are due to a lesion (increased :MIBI uptake) in that breast or 
occasionally due to diffuse increased uptake in that breast. 
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Figure 4.4. lllustrate the individual and mean values for (a) malignant (b) benign 
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Figure 4. 7. Relationship between counts per pixel versus TIB ratio in each breast 
(a) 
(b) 
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Figure 4. 8. Illustrate the number of counts per pixel in lesions detected in right and left 
breasts on SMM. 
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4.6. BIOPSY VS SCINTIMAMMOGRAPHY VS MAMMOGRAPHY RESULTS 
The comparative results of SMM and mammography were compared with biopsy 
results, considered as a standard. These results are illustrated in tabulated form in Table 
4.7. 
Table 4.7 includes a patient who showed 2 lesions (1 indeterminate & I malignant) 
in one breast on SMM, but the mammography and biopsy results indicated that both 
lesions were consistent with benign pathology (fibrocystic disease) . 
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Table 4. 7 Comparison Between Histopathological, Tc-99m Scintimammographic and 
Mammography Results 
Lesions (n) Histology SMM Mammo Comment 
14 Malignant Positive Positive 
1 Malignant Positive Negative 
2 Malignant Positive Indeterminate 
2 Malignant Indeterminate Positive Lobular ca (2) 
1 Malignant Negative Positive Adeno ca 
1 Malignant Negative Negative Ductal ca 
1 Malignant Indeterminate Negative Phylloides T 
15 Benign Negative Negative 
9 Benign Indeterminate Negative 
·s Benign Positive Negative 
1 Benign Negative Indeterminate F/adenoma 
1 Benign Positive Indeterminate F/adenoma 
1 Benign Indeterminate Indeterminate Lipoma 
* One of these breasts showed further 2 lesions on SMM which were clinically impalpable 
and therefore were not biopsied 
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Fourteen histologically confirmed malignant breast tumours and 15 benign lesions 
showed concordant SMM and mammography results. 
Eight benign breast lesions showed negative mammography but positive SMM 
scans (false +ve SMM). This includes a patient (patient 24) with 3 lesions in one breast 
(one palpable and 2 nonpalpable) . All 3 lesions were positive on SMM. The 2 nonpalpable 
lesions were not biopsied as they were negative on mammography. 
In one patient (patient 44) mammography detected a small lxl cm solid lesion 
confirmed to be an adenocarcinoma in situ, in a clinically normal breast. The SMM scan 
was negative in this case (false -ve SMM). In another patient with a clinically solitary 
lump, SMM showed 2 separate lesions (one clinically palpable and the other nonpalpable) 
in that breast and were classified as positive and indeterminate. Mammography showed 
features suggestive of benign pathology and were confirmed on biopsy results (both 
lesions were consistent with fibrocystic disease). 
Thirteen lesions in 11 breasts had indeterminate results on SMM, out of which 9 
lesions (in 8 breasts) showed benign pathology and negative mammography. Two lesions 
in a breast were malignant on biopsy and had positive mammography. Further 2 lesions 
were detected on SMM as indeterminate. One was malignant with negative mammography 
and the other a benign lesion with indeterminate mammography. 
The most important group consisted of five breasts with indeterminate 
mammography results, of which one breast had an indeterminate SMM result. The 
histology.on this lesion showed features of benign disease (lipoma). Two breasts had 
positive SMM scans and histology results confirmed malignant lesions. Of the remaining 2 
breasts, one showed a false positive SMM scan and no uptake in the other. Both of these 
breasts had a fibroadenomas on histology. 
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4.7. STATISTICAL ANALYSIS 
The statistics were based on the number of histopathologically reported biopsied 
lesions. Comparison of summarised results statistics between SMM and mammography for 
formal and pilot studies is shown below in Table 4.8 (a). If all indeterminate SMM results 
were considered as negatives, then for the formal study, SMM results showed a sensitivity 
of 89.5%, specificity of76.3% and accuracy of 80.7%. Table 4.8 (b) shows similar results 
for the pilot and formal studies combined together. 
Sensitivity: (true positives/true positives + false negatives) 
Specificity: (true negatives/true negatives + false positives) 
PPV: positive predictive value (true positivesltruepositives + false positives) 
NPV: negative predictive value (true negative/true negatives + false negatives) 
Accuracy: ( true positives + true negatives/ total number) 
IND: Indeterminate 
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Table 4. 8. Summary of results statistics, (a) formal and pilot studies (b) whole study. 
(a) 
FORMAL STUDY PILOT STUDY 
SMM MAMMO SMM MAMMO 
Sensitivity: (17/19) 89.5% (16/20) 80% (4/4) 100% (4/4) 100% 
Specificity: (16/25) 64% (32/32) 100% (6/8) 75% (3/3) 100% 
Accuracy (33/44) 75% (48/52) 92.3% (10/12) 83.3% (7/7) 100% 
PPV: (17/26) 65% (16/16) 100% (4/6) 66.6% (4/4) 100% 
NPV: (16/18) 89% (32/36) 89% (6/6) 100% (3/3) 100% 
(b) 
WHOLE STUDY (PILOT AND FORMAL) 
SMM MAMMO 
Sensitivity: (21/23) 91.3% (20/24) 83.3% 
Specificity: (22/33) 66. 7% (35/35) 100% 
Accuracy {43/56) 76.8% (55/59) 93.2% 
PPV: (21/32) 65.6% (20/20) 100% 
NPV: (22/24) 91.6% (35/39) 89.7% 
53 
Results 
4.8. AXILLARY LYMPH NODE INVOLVEMENT: 
Six out of 21 patients with breast cancer were found to have metastatic ipsilateral 
axillary lymph node involvement on histology. For these 6 patients, SMM showed 3 and 
mammography one concordant result. SMM and mammography could not detect ipsilateral 
axillary lymph node involvement in the rest of 3 and 5 patients (false -ve), respectively. 
SMM showed positive lymph node involvement in a further 5 patients in which the 
biopsy results were negative (false +ve SMM). Two of these patients also showed features 
of metastatic lymph node involvement on mammography. 
The diagnosis of lymph node involvement shown by SMM and mammography are 
compared with the histological results in Table 4.9. It must be remembered that this is not 
sentinel node imaging which is done specifically for the lymphatic system using colloids. 
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Table 4. 9: Comparison behveen Tc-99m MIBI scan, Mammography and Biopsy Results 
In Axillary Lmph Node Involvement 
Paient No. Histopathology Metastatic Lymph Node Involvement 
Biopsy SMM Mammography 
1. Ductal Ca P (2/17) N N 
2. Ductal Ca P (5/12) p N 
3. Ductal Ca P (3/10) N N 
Poorly Diff ereniated 
4. Ductal Ca N p N 
5. Ductal Ca p (1/7) N N 
6. Fat N ecr.& lnflamm. N p N 
7. Ductal Ca N p p 
8. Ductal Ca p (1/12) p p 
9. Ductal Ca N p N 
10. Ductal Ca p (1/6) p N 
11. Ductal Ca N p p 
(P = Positive, N = Negative, (number.of L.N involved I number. of nodes explored). 
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CHAPTER FIVE 
ADDITIONAL STUDY 
56 
Additional Study 
5.1 INTRODUCTION 
Despite recent improvements in mammographic techniques and equipment 
radiologically dense breasts continue to to be difficult to image and evaluate. Patients with 
nondiagnostic mammographic lesions, especially those with architectural distortion due to 
previous surgery or radiation therapy may benefit from a nuclear scan which is 
independent of breast density or distortion and can therefore make a significant 
contribution to clinical management in patients with clinically suspected breast 
abnormalities. 
As the results of our formal study and those of others [21,84] suggest that SMM 
has high sensitivity and negative predictive value, it could be useful in patients with 
indeterminate mammographic results. Therefore we conducted an additional prospective 
study in 25 patients with palpable breast lesions and indeterminate mammography. 
5.2. LITERATURE REVIEW 
Khalkhali et al. [21] have shown the usefulness of SMM in patients with dense 
breasts on mammogram. In 48 patients with palpable breast lesions, not clearly interpreted 
by mammography, SMM showed a sensitivity of93 .7 % and specificity of90.6 % as 
compared to a sensitivity of 82.2 % and specificity of 46.1 % by standard mammography. 
According to Mekhmandarov et al. [85] SMM improved the diagnostic accuracy in cases 
of palpable breast lesions with probably normal or indeterminate mammographic results. 
According to Prat et al. [86], the use of a joint mammography-SMM diagnostic 
protocol could significantly reduce the number of biopsies performed in patients with 
breast lesions of low or indeterminate mammographic suspicion of malignancy. 
Bombardieri et al. [8] have also proposed SMM as a complementary examination in 
patients with difficult to interpret mammograms, as is most often the case in patients with 
high breast density. 
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5.3. METHODOLOGY 
5.3.1. PURPOSE 
This subgroup of patients was studied to determine whether Tc-99m MIBI 
scintimammography can differentiate between benign and malignant breast lesions in 
patients with clinically palpable breast lumps and indeterminate mammography. 
5.3.2. SAMPLE SELECTION 
The study population consisted of25 women between ages of 34 and 80 years with 
a mean age of 4 7 years. 
The selection criteria differed from those in the main (formal) study in that only 
patients with indeterminate mammography were selected. In addition, clinical evaluation, 
scintimammography and data recording were integrated to ensure that there could be 
"lesion by lesion " comparison of each breast lesion detected by clinical examination or 
scintimammography or both with the biopsy results of that particular lesion. 
The rest of the criteria for patient selection were the same as for the formal study. 
All patients were selected by an experienced surgeon at the Combined Breast 
Clinic at Groote Schuur Hospital. The patients selected for breast scan (SMM) underwent 
biopsy on the same day. As in the main study, mammography and SMM were done before 
biopsy. 
All patients gave informed consent before SMM and the research was explained to 
them. 
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5.3.3. PROCEDURE 
Tc-99m MIBI SMM scan were performed using fractionated Cardio/ite produced 
by Du Pont Pharmaceuticals of USA. 
Each vial contains: 
Tetrakis (2-methoxy isobuty/ isonitri/e) 
copper(l) tetrafluoroborate 
Stannous chloride dihydrate 
L-cysteine hydrochloride monohydrate 
1.00mg 
0.075 mg 
1.0mg 
For reconstitution with oxidant-free Sodium Pertechnetate Tc-99m injection. 
We used fractionated Cardiolite for this study because locally produced sestamibi 
(Myotek) was no longer commercially available. Fractionation of Cardiolite was 
performed using exactly the same method as for Myotek in the formal study. Each 
sestamibi vial was reconstituted with sterile saline and divided into 10 fractions . 
The reconstituted sestamibi was stored in a chest freezer at a temperature below 
(-) 10°C. In order to compensate for oxidation of tin during the storage of sestamibi, 
additional tin was added to the fractionated sestamibi. The tin was obtained from invivo 
Red Blood Cell Labelling Agent, manufactured by AEC of South Africa. Each vial of 
in vivo Red Blood Cell Labelling Agent contains 2504g of tin. 
When required, the individual dose was thawed at room temperature and mixed 
with Tc-99m pertechnetate. Each dose was prepared using the same method as used in the 
formal study. 
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5.3.3.1. Quality Control of Fractionated Tc-99m Sestamibi 
Each reconstituted dose was tested before use, to ensure high labelling efficiency. 
In this study we also used the ascending paper chromatography procedure as for the 
formal study. 
The radiochemical purity of the Tc-99m MIBI injected into the patients was 
always more than 90% (see Fig 5.1.) 
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5.3.3.2. Scintimammography Procedure 
The SMM methods regarding patient and camera position and acquistion 
parameters were exactly the same as for the formal study. Similarly, total counts obtained 
in each view were recorded. On the lateral view, irregular regions of interest were drawn 
around each breast excluding chest wall . The total counts in each ROI and area in pixels 
were used to calculate counts per pixel for each breast. The data can be seen in Table 6 of 
Appendix B. Semiquantitative analysis (target to background ratios) were also performed 
as in the formal study. 
5.3.3.3. Scan Interpretation 
The scans were classified as positive, negative and indeterminate using the same 
criteria of visual assessment as for the formal study. 
All scans were evaluated by the researcher and another experienced nuclear 
medicine physician. 
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5.4.RESULTS 
Table 5.1. summarises the total number of breast lesions and clinical, 
scintimammography and biopsy findings: 
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5.4.1. CLINICAL EXAMINATION 
A total of 29 lesions were palpated in 26 breasts of 25 patients on clinical 
examination. Solitary breast lesions were present in 22 breasts. One patient had bilateral 
breast lumps, one in her right and 2 in the left breast (Patient 20). A further 2 patients 
(patients 6 and 18) had 2 lesions in one breast. 
One patient had a clinical suspicion of tumour recurrence. Six patients had a 
positive family history of breast cancer. Three of the patients were nulliparous, including 
one with a positive family history of breast cancer. 
The distribution of 29 breast palpable breast lesions in 25 patients (26 breasts) are 
shown in Table 5.2. with the Tc-99m MIBI SMM results. 
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Table 5.2: Number and Distribution Of Lesions On Clinical Examination and 
Scintimammography. 
RIGHT BREAST Palpable Lesions Lesions Total 
Lesions on Detected on Detected on Lesions 
Clinical SMM Clinical 
Exam. Exam. & 
SMM 
Upper Outer Quadrant: 10 9 5 14 
Upper Inner Quadrant: 3 4 1 6 
Lower Outer Quadrant: 1 3 1 3 
Lower Inner Quadrant: 1 1 1 1 
Other / Periareolar: 4 4 3 5 
TOTAL 19 21 11 29 
LEFT BREAST Palpable Lesions Lesions Total 
Lesions on Detected on Detected on Lesions 
Clinical SMM Clinical 
Exam. Exam. & 
SMM 
Upper Outer Quadrant: 4 2 2 4 
Upper Inner Quadrant: 2 1 0 3 
Lower Outer Quadrant: 2 3 2 3 
Lower Inner Quadrant: 0 0 0 0 
Other / Periareolar: 2 2 2 2 
TOTAL 10 8 6 12 
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5.4.2. TECHNETIDM-99m MIBI SCINTIMAMMOGRAPHY RESULTS 
All 25 patients had SMM scan. 
The right breast showed 21 and left breast 8 lesions on SMM as shown in 
Table 5.2. 
Of 29 clinically palpable lesions, 17 were detected on SMM (15 positive, 2 
indeterminate). The other 12 lesions were regarded as negative on SMM. 
Of 29 lesions detected on SMM (17 positive and 12 indeterminate), 17 were 
palpable and 12 were non palpable. 
In the right breast upper outer quadrant, 9 lesions were detected on SMM. Five 
were classified as positive and 4 as indeterminate. Of the 5 positives, 4 were shown to be 
malignant and one benign on biopsy. Out of 4 indeterminate lesions on SMM, one was 
benign on biopsy while the other 3 lesions were nonpalpable and were not biopsied. There 
were 5 palpable lesions which were negative on SMM. All of these were shown to be 
benign on biopsy. 
In the right upper inner quadrant, 4 lesions were seen on SMM. One was malignant 
on biopsy while 3 non palpable lesions were indeterminate and were not biopsied. Two 
palpable lesions were negative on SMM. 
In the right lower outer quadrant 3 lesions were detected on SMM. One was shown 
to be malignant on biopsy (patient 13) while 2 were indeterminate on SMM. Both these 
lesions were clinically non palpable. One was shown to be benign lesion ( patient 15) 
while the other was not biopsied (patient 8). 
In the right lower inner quadrant, a clinically palpable lesion was positive on 
SMM. This lesion was shown to be a benign lesion on biopsy (patient 22). 
In the right breast periareolar area, 4 lesions were seen on SMM. Of these, 3 were 
palpable and one non palpable. Two were positive on SMM and shown to be malignant; 
while one was indeterminate on SMM and was confirmed to be a benign lesion on biopsy. 
The clinically impalpable lesion in the deep breast tissue was detected on SMM but its 
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exact position could not be determined on the scan. It was regarded as positive on SMM 
but could not be biopsied as it was nonpalpable and situated in a clinically and 
mammographically normal breast. Another palpable lesion in the periareolar region was 
negative on SMM and confirmed to be a benign lesion on biopsy (patient 14). 
In the left breast upper outer quadrant 2 lesions were seen as positive on SMM. 
Both were benign on biopsy, while the other 2 palpable lesions did not show any MIBI 
uptake (negative SMM). Both were benign on biopsy. 
In the left breast upper inner quadrant SMM detected an indeterminate lesion 
which was clinically non palpable and was not biopsied; while 2 palpable lesions were 
negative on SMM. Both these lesions were shown to be benign on histology. 
In the left breast lower outer quadrant 3 lesions were detected on SMM. Two were 
palpable and one non palpable. Both palpable lesions were positive on SMM and were 
shown to be benign on biopsy, while the non palpable lesion was regarded as 
indeterminate on SMM and was not biopsied. 
There were no lesions present in the left breast lower inner quadrant on clinical 
examination or on SMM. 
In the left periareolar area 2 lesions were seen as positive SMM. One was shown to 
be malignant while the other one benign on biopsy. 
In total 41 lesions in 30 breasts were evaluated on SMM. Of these, 17 were 
regarded as positive, 12 as negative and 12 as indeterminate on SMM The results are 
shown in Table 5 .1. 
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5.4.3. BIOPSY RESULTS 
All 25 patients had biopsies. A total of 41 lesions in 30 breasts were detected on 
clinical examination and SMM. Of these, 29 palpable and 2 nonpalpable lesions in 26 
breasts were biopsied, while 5 non palpable lesions, detected only on SMM, were not 
biopsied. Further 5 nonpalpable lesions in 4 breasts, detected only on SMM, also were not 
biopsied. All these nonpalpable lesions could not be biopsied because the surgeon could 
not locate the exact site to biopsy. 
The only patient (patient 7) in this subgroup of 25 patients, with clinically 
suspected tumour recurrence, had fibroadipose tissue on cytology examination. 
Five of the 6 patients with positive family history of breast cancer had benign 
breast lesions, while one had 2 malignant lesions in one breast. Out of the 3 nulliparous 
patients, one had a squamous cell carcinoma, one had atypical ductal hyperplasia and the 
third had a breast cyst. 
A total of9 malignant lesions in 7 breasts were confirmed on histology. Eight 
lesions in 6 breasts were infiltrative ductal carcinomas. These include a patient (patient 6) 
with 2 clinically palpable lesions in her right breast and a patient (patient 15) who had a 
clinically palpable breast lesion but showed further 2 nonpalpable lesions on SMM. Of 
these 2 nonpalpable lesions, one was regarded as positive on SMM and confirmed to be 
another ductal carcinoma on biopsy, while the other the other lesion was indeterminate on 
SMM and was proven to be normal breast tissue. One patient had solitary squamous cell 
carcmoma. 
There were 22 benign lesions noted in 20 breasts in 19 patients. These lesions 
included 2 patients each with 2 palpable lesions in one breast (patients 18 and 20) and 
another patient with a benign lesion together with 2 malignant lesions in one breast 
(patient 15). 
The histopathological results are listed in Table 5.3 . 
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Table 5.3: Summary o/Histopathological Results o/25 patients with 31 breast lesions. 
IDSTOPATHOLOGY LESIONS BREASTS 
Malignant Tumours: 
Infiltrative Ductal ca. 8 5+1 • 
Squamous cell ca. 1 1 
Benign Tumours: 
Fibroadenoma 5 5 
Other Benign Lesions: 
Fibrocystic Disease 4 3 
Fibroadipose Tissue 2 2 
Fat Necrosis 1 1 
Fibrosis 2 2 
Inflammatory Lesions 1 1 
Cyst . 3 3 
Atypical Ductal Hyperplasia 1 1 
Normal Breast Tissue 3 1+ 1 * 
Total 31 26 
. . . . . 1 (Patient 15); one breast had 3 lesions (2 infiltrative ductal carcinomas and one 
normal breast tissue). 
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5.4.4. TECHNETIUM-99m MIBI SCINTIMAMMOGRAPHY VS BIOPSY 
RESULTS 
Table 5.4.: Summary of Histopathological and Tc-99m Scintimammography Results. 
HISTOLOGY 
Malignant Benign 
Positive 9 7 
Negative 0 12 
Indeterminate 0 3 
As shown in Table 5.4. SMM had positive results in all 9 malignant breast lesions 
in 7 patients. In patients with palpable malignant breast lumps, there were no negative or 
indeterminate SMM scan findings. 
However, in 3 of these 7 patients with malignant lesions SMM detected further 6 
lesions in 4 breasts which were clinically non palpable. Of these, one lesion showed ductal 
carcinoma on histology in a patient (patient 15) who also had a clinically palpable 
infiltrating ductal carcinoma in the same breast. Both these lesions were positive on SMM. 
The other 5 nonpalpable lesions seen on SMM were classified as indeterminate. Of these, 
one was shown to be a normal breast tissue (patient 15) while the rest of 4 lesions were not 
biopsied as the surgeon was not able to identify an area to biopsy. 
There were a total of 22 benign lesions in 20 breasts. This included a patient 
(patient 15) with a nonpalpable lesion, regarded as indeterminate on SMM and confirmed 
to be normal breast tissue on histology. This patient had further 2 lesions in the same 
breast (both infiltrative ductal carcinoma). Twelve lesions in 10 breasts showed negative 
SMM scans i.e. no MIBI uptake. This includes a patient (patient 20) with bilateral 
fibrocystic lesions. There were 7 lesions in 7 breasts which showed positive MIBI uptake. 
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Out of these 7 lesions, 5 were fibroadenomas. Further 3 lesions in 3 breasts were classified 
as indeterminate on SMM. 
In these patients with benign breast lesions, SMM detected 6 extra lesions in 5 
breasts of 5 patients. All of these lesions were clinically non palpable and none of them 
were biopsied. One of the lesion was classified as positive and the rest of 5 as 
indeterminate on SMM. 
Scintigraphic results for each pathological diagnosis are give in Table 5.5 . 
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Table 5.5. Scintigraphic Findings Co"elating with Histopathological Results. 
Histology Number of Tc-99m MIBluptake 
Lesions Positive Negative Indeterminate 
Infiltrative Ductal Ca. 8 8 0 0 
Squamous Cell Ca. 1 1 0 0 
Fibroadenoma 5 5 0 0 
Fibrocystic Disease 4 0 3 1 
Cyst 3 0 2 1 
Fat Necrosis 1 0 1 0 
Atypical Duct Hyperplasia 1 1 0 0 
Fibrosis 2 1 1 0 
Fibro Adipose Tissue 2 0 2 0 
Inflammatory Lesions 1 0 1 0 
Normal Adipose Tissue 3 0 2 1 
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5.4.5. SEMIQUANTITATIVE ANALYSIS (T/B RATIOS) 
Malignant breast lesions usually showed higher TfB ratios as compared to benign 
lesions. Figures 5.2 a and b show TfB ratios in malignant and benign lesions. TfB ratios of 
lesions which were not biopsied are not included in these graphs. 
Figures 5.3 a and b show the relationship between counts per pixel in right and left 
breast (x axis) with TfB ratio value (y axis) of the lesion detected in the breast. These 
figure show that there is no linear relationship between counts per pixel in a breast and 
TfB ratio. 
Figure 5. 4 shows distribution of the counts per pixel in the lateral view of each 
breast of each patient. The points that lie further from the diagonal line show more counts 
per pixel in that breast and is mostly due to a lesion (increased MIBI uptake) in that breast. 
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Figure 5.2. The individual and mean values for (a) malignant and (b) benign breast 
lesions 
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Figure 5.3. Relationship between counts per pixel versus TIB ratio 
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Figure 5. 4. The number of counts per pixel in lesions detected in right and left breasts 
onSMM. 
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5.4.6. STATISTICAL ANALYSIS 
Our study showed a sensitivity of I 00% and specificity of 63% in detecting 
malignant breast lesions, in this subgroup of patients. The accuracy was shown to be 75%. 
The negative and positive predictive values were I 00% and 56% respectively. 
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5.4. 7. AXILLARY LYMPH NODE INVOLVEMENT 
In this series 5 of the patients with malignant breast tumours had axillary lymph 
node clearance. None of the excised lymph nodes showed metastatic involvement. 
However, SMM: showed definite focal increased MIBI uptake in ipsilateral axillary lymph 
nodes of 2 patients with infiltrative ductal carcinomas in their breasts. The axillary lymph 
nodes were also visible on mammography but were not palpable. In one of these patients 
no cancerous lymph nodes were noted on histology while in the other patient axillary 
clearance was not performed. 
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CHAPTER SIX 
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6.1. RADIOPHARMACEUTICAL USED IN THIS STUDY 
Fractionation reduces the costs of using sestamibi and makes the method affordable. We 
used locally produced sestamibi for our pilot and formal studies. One vial of South African 
produced sestamibi (Myotek) used to cost R 1014.60. Our hospital cannot afford to use one vial 
per patient. However one vial can be divided into ten fractions, reducing the cost of an 
individual dose ofMyotek to R 101.46. This is affordable and the decision to use it for SMM 
then rests on sensitivity, specificity and accuracy, not cost. Indeed, fractionation is so useful 
that aliquots can be used over a period of 6 months from the date of initial reconstitution [87]. 
Sampson has suggested that, provided full testing and validation of the product is performed, kit 
splitting is an acceptable alternative to the manufacturer's recommended method [82]. 
Unfortunately, the locally produced sestamibi (Myotek) was no longer available 
commercially at the time when we decided to do an additional study on 25 patients. Therefore 
we used Cardiolite ® produced by Du Pont Pharmaceuticals, USA. Each vial of Cardiolite ® was 
also divided into ten fractions using the same procedure as for Myotek, in order to reduce the 
cost. 
The principle of achieving cost savings by fractionating various radiopharmaceuticals 
has been described by many other workers [88-91]. Solanki et al. [92,93] developed a method of 
fractionation of hexamethylpropyleneamine oxime (HMP AO). They found that, at the time of 
radiopharmaceutical preparation, additional tin was required to compensate for the tin that was 
oxidised during the storage period. This method of tin enhancement was applied successfully to 
leukocyte labelling and cerebral perfusion studies. In particular, it was demonstrated that 
cerebral perfusion SPECT scans performed with unfractionated and fractionated HMP AO did 
not significantly differ from each other. This implies that the biodistribution of the fractionated 
HMPAO does not differ from that of the unfractionated product. Baker [94] demonstrated, using 
chromatography, animal biodistribution studies and imaging, that fractionated and tin-enhanced 
HMP AO and MIBI produced the same results as the unfractionated product. Similarly, 
Chowdhury and Hung [88], using high pressure liquid chromatography (HPLC) on fractionated 
and tin-enhanced sestamibi (Cardiolite®), have shown identical radiochemical species in both 
the regular and fractionated product. 
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Mr. John Boniaszczuk and Dr. Michael J Byrne from our department extended the 
principle of fractionation and tin-enhancement to the South African produced MIDI (Myotek). 
They decided to fractionate to ten fractions as this had been validated by others [89,93]. As a 
precaution against oxidation of the tin in the original vial, we added additional tin at the time of 
radiopharmaceutical preparation. This approach of tin-enhancement of fractionated kits is based 
on the work of Solanki et al. [93] and has been successfully applied by others [88,94]. 
We stored fractionated Myotek at (-)4°C for our pilot and formal studies. Storage 
temperatures recommended for fractionated kits appear to vary considerably in the literature, 
ranging from (-)70°C to (-)10°C [88,89,95,96]. All these authors store thy fractionated kits in 
frozen form. Nevertheless, storage temperature for Myotek appeared to be satisfactory, as the 
radiochemical purity of the MIDI was always between 89% to 98%, except for one case where it 
was 80%. However, for the additional study, we stored the reconstituted Cardiolite® in a chest 
freezer at a temperature below (-) 10°C as recommended by most authors aforementioned. We 
always achieved radiochemical purity of sestamibi of 90% or more at this storage temperature. 
6.2. CAMERA AND PATIENT POSITIONING AND IMAGING 
Positioning and acquisition parameters are important in obtaining high quality images. 
Initially breast imaging protocols using Tl-201 relied on supine techniques in which the patient 
was positioned supine with the arms raised in order to evaluate both breasts and the axilla [9]. 
Theoretically the potential for not localising a deep lesion against the chest wall using the supine 
only technique was of concern. Khalkhali et al. [97] and Diggles et al. [ 40] developed a prone 
imaging technique using MIDI. A specially designed table allowed the patient to be placed in a 
prone position with the breast dependent. We adopted a combination of prone and supine 
imaging which seems to be the method of choice [7,18]. We used the conventional gamma-
camera bed, rather than a specially designed table or table overlay, and made it comfortable for 
the patients by placing thin pillows at the lateral edges of the bed. Diggles and co-workers [ 40] 
have shown that the technique of planar prone breast imaging is more favourable than imaging 
in the supine position because of excellent separation of breast tissue from the thoracic wall . 
Relaxation of the pectoralis muscles allows evaluation of deep breast tissue adjacent to the chest 
wall. This position also excludes any activity from the contralateral breast and improves 
separation of the breast tissue from the liver and myocardium, allowing improved lesion 
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detection. They also showed that prone dependent breast imaging results in visualization of 
more breast tissue, as well as a natural breast contour, which aids in lesion localization. 
Incorrect positioning, such as accidental compression of the breast on the imaging table, 
can produce false localisation. Extending the ipsilateral arm over the head allows the axilla to 
come into contact with the collimator surface and be included in the field of view. A potential 
disadvantage of a lateral view is the possibility of missing a small or low-intensity medial lesion 
because of attenuation. 
The timing of the examination is another important matter. Much experience with MIBI 
in oncology seems to confirm that adequate visualization of neoplastic lesions can be obtained at 
10 minutes after injection [13] . In our study, imaging was started 5 minutes after intravenous 
injection of the tracer, in the contralateral arm. The opposite arm was injected in order to 
minimise the potential of transient adherence of the tracer to the regional veins after the 
injection, making evaluation of the axilla and upper breast somewhat difficult. Because of initial 
high lung background, the anterior supine image was obtained after the lateral images. 
A radioactive anatomical marker was used as an additional guide in localising the site of 
a lesion in a breast quadrant. 
The image zoom of factor 2 was selected for lateral and posterior oblique views, except 
in patients with very large breasts, for whom appropriately less magnification was selected in 
order to include the entire breast in the field of view, keeping the breast in the centre of the field 
of view. This acquisition magnification improved the quality of images. 
6.3. INTERPRETATION OF SCINTIMAMMOGRAPHY RESULTS 
Various investigators have developed different criteria for interpretation of SMM results. 
Our criteria for interpretion was essentially visual, as any focal lesion with uptake above the 
normal breast activity was considered malignant. However, many benign breast lesions showed 
increased MIBI uptake. We used 3 categories for SMM scan interpretation: positive, negative 
and indeterminate. The criteria for these categories are defined in section 3. 3. 5. of Chapter 3 
(pages 27,28). Total counts obtained in each view were recorded to ensure that enough counts 
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were acquired for each image. We also recorded the counts per pixel in each breast on lateral 
view, as it always best separates the breast from the chest wall, by drawing an irregular region 
of interest around the breast excluding chest wall. This was to demonstrate the difference of 
activity (count rate) between two breasts. Higher counts in a breast is usually due either to a 
lesion with increased tracer uptake or less frequently due to high counts in the entire breast as 
compared to the contralateral breast, which may be regarded as a normal variant. The graphs 
dipicting these results is shown in Figures 4.7(a,b) and 5.3. The data on individual patients with 
these results can be seen in Tables 4, 5 and 6 (for pilot,formal and additional studies, 
respectively) in Appendix B. The objective assessment was done using target to background 
ratio technique on each breast lesion detected on Sl\1M. 
Definitions for interpretation of positive, negative and indeterminate Sl\1M in literature 
are not entirely consistent, for example Burak et al. [14] and Taillefer et al. [18] have used 
different criteria of interpretation for Sl\1M in their papers. When we tried to apply Burak's 
criteria to our data, indeterminate scans in our study were regarded as positive according to 
Burak's criteria, as they did not have a category for indeterminate Sl\1M. On the other hand 
Taillefer et al. [18] did have provision for an indeterminate Sl\1M scan but did not define it. 
We compared the results of our formal study, using Burak et al. [14] and Taillefer et al. 
[18] criteria with those of ours in order to demonstrate that our criteria for interpretation of 
Sl\1M scan were as reliable as those of others. 
Burak et al. [14] in their study, had evaluated all images semiquantitaively. The lesions 
were graded as: 0: less than background activity; 1: equal to background activity; 2: less than 
heart but more than background activity; 3: equal to heart activity and 4: more than heart 
activity. When compared to our criteria for different categories, their grades O and 1 
corresponded to our category for negative, as it suggests no increased MIBI uptake. Likewise, 
their grades of 2, 3 and 4 corresponded to our categories for indeterminate and positive. It must 
be emphasised that in Burak's criteria there was no category for an indeterminate Sl\1M. 
Taillefer et al. [18] defined positive Sl\1M result for malignant breast tumour as a focal 
area of increased MIBI uptake compared to the surrounding normal breast tissue which 
corresponded to our category of positive Sl\1M scan. There is no specific description of the 
criteria for an indeterminate Sl\1M scan in their paper. They used a semiquantitative analysis 
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technique to determine the relative degree of diagnostic certainty. These included, 0: definitely 
normal; 1: probably normal; 2 : equivocal; 3: probably abnormal and 4: definitely abnormal. 
When compared to our categories, their categories of O and 1 corresponded to our category for 
negative, their category of2 corresponded to our category for indeterminate and their categories 
of 3 and 4 corresponded to our category for positive SMM scan. 
Ifwe re-analyse our data using Burak et al. (14] or Taillefer et al (18] criteria and 
compared those results with ours, the results we would have got are shown in Table 6.1 (a) and 
(b) . 
Table 6.1. Summary of Comparative Results using Burak's (a) and Taillefer's (b) Criteria of 
SMM with our Results and Histology. 
(a) 
HISTOLOGY Sl\1M Sl\1M LESIONS 
Our study Burak et al. [14] 
Malignant Positive Positive 17 
Malignant Negative Negative 2 
Malignant Indeterminate Positive 3 
Benign Negative Negative 16 
Benign Positive Positive 9 
Benign Indeterminate Positive 10 
Not done (non- Positive Positive 2 
palpable lesions) 
(b) 
IDSTOLOGY Sl\1M Sl\1M LESIONS 
Our study Taillefer et.al [18] 
Malignant Positive Positive 17 
Malignant Negative Negative 2 
Malignant Indeterminate Indeterminate 3 
Benign Negative Negative 16 
Benign Positive Positive 9 
Benign Indeterminate Indeterminate 10 
Not done (non- Positive Positive 2 
palpable lesions) 
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There were 2 malignant breast lesions in 2 patients which showed negative SMM 
according to our, Burak's and Taillefer's criteria. 
One of the patients had a clnically palpable lump situated at upper outer quadrant of the 
breast. On histology a 2xl cm recurrent infiltrating ductal carcinoma was confirmed. 
Mammography was also negative in this patient. All the other 14 infiltrative ductal carcinomas 
were positive on SMM on all 3 criteria. The mammogram showed positive results on 12 of these 
lesions while 2 lesions were classified as indeterminate. 
Palmedo et al. [15] in their study showed 3 false negative SMM, using Tc-99m MIBI, 
out of a total of 22 breast lesions. Two were invasive ductal carcinomas, including one with 
local tumour recurrence and was clinically palpable while the other was nonpalpable. The third 
lesion was clinically palpable recurrent invasive lobular carcinoma. Two of these lesions were 
located in the medial part of the breast and were less than 1 cm in diameter. Mammography was 
not performed in 2 cases with suspected recurrent breast cancers and was negative (false 
negative) in one case. Rest of the 12 malignant lesions (all ductal carcinomas) were positive on 
SMM in their study. Similarly Khalkhali et al. [16] showed 4 false negative lesions on SMM out 
of 153 breast lesions. All were infiltrating ductal carcinomas (4 palpable and one nonpalpable). 
All of these lesions were less than 1 cm in diameter and were located in medial aspect of the 
breast. Rest of33 patients with ductal carcinomas were positive on SMM. Tiling et al. [84] 
showed 6 false negative SMM out of 82 patients with indeterminate and / or clinical 
examination. Four of these were infiltrative and 2 were ductal carcinoma in situ. Rest of the 15 
lesions with ductal carcinomas were positive while 5 were indeterminate on SMM. The mean 
diameter of all the tumours was 2.1 cm and the smallest carcinoma was 2 mm in greatest 
dimension. Taillefer et al. [18] showed 4 out of38 ductal carcinomas (including a microscopic 
ductal ca in situ) as negative (false negative) on SMM and the rest of 34 lesions as positive. 
Burak et al. [ 14] showed positive SMM all 19 patients with infiltrative ductal carcinomas. The 3 
false negative SMM included 2 with invasive lobular and one with tubular carcinoma. 
Another lesion with false negative SMM in our study was clinically nonpalpable small 
(10 mm in diameter) adenocarcinoma in situ. It was detected as a suspicious lesion on 
mammography. This was the only patient with adenocarcinoma in our study. Kao et al. [12] 
showed 27 adenocarcinomas (84%) in their study with 32 patients with palpable breast lesions. 
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Out of these, 4 adenocarcinomas could not be detected on SMM. The smallest detectable cancer 
measured 2xlxl cm, while the largest undetectable carcinoma measured 7x4x3 cm on 
mammography. None of tumours in their study were less than 1 cm in size. Adenocarcinoma of 
the breast appeared to be a relatively uncommon tumour type as non of the patients had this 
tumour in studies conducted by Palmedo et al. [15], Khalkhali et al. [16], Tiling et al. [84], 
Taillefer et al. [18] and Burak et al. [14]. 
It is possible that false negative SMM is associated with small (less than 1 cm) size and / 
or with the metabolic activity of the tumour, and not the tumour type. 
Burak et al. [14] did not have an indeterminate category in their study. There were 3 
malignant lesions in 2 breasts which were indeterminate on SMM according to our and 
Taillefer's criteria and were categorised as positive according to Burak's criteria. 
One of these patients (patient 17) had 2 lowgrade ill defined foci close to each other. 
Histology confirmed these as invasive lobular and lobular carcinoma in situ. The mammogram 
also showed features of malignancy. Rest of the 2 lobular carcinomas in our study, showed 
positive SMM on our, Burak's and Taillefer's criteria. The mammogram was negative in one 
and positive in the other case. The other patient had a low malignancy type Phylloides tumour. 
The tumour showed illdefined and lowgrade uptake and was not classifiable as benign or 
malignant according to our or Taillefer's criteria.The mammography was negative (false 
negative).This was the only patient with Phylloides tumour in our study. 
Tiling et al. [84] in their study showed 5 indeterminate breast lesions on SMM in the 
malignant group. All were ductal carcinomas. However, their criteria for indeterminate SMM 
was different from ours. They classified diffuse uptake with high intensity (uptake comparable 
to or higher than the upper chest as seen in the lateral projection) as indeterminate, while diffuse 
uptake with low intensity was interpreted as probably benign. On the other hand, we classified 
any area of illdefined diffuse uptake as indeterminate, including low intensity uptake. They 
showed 2 false negative SMM (probably benign) which would be indeterminate according to our 
criteria, hence reducing the number of false negatives. 
Ten patients with 10 benign lesions were categorised as indeterminate according to our 
and Taillefer's criteria and as positive on Burak's criteria. Out of these 10 lesions, 4 were 
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inflammatory lesions, 2 with fibrocystic disease, 2 with fat necrosis, 1 with lipoma and 1 with 
fibroadipose tissue. The mammography showed features suggestive of benign pathology. 
Tiling et al. [84] in their study showed 7 out of 53 benign breast lesions as indeterminate 
on SMM. Out of these 7, 4 were fibroadenomas, 2 fibrocystic and one with an inflammatory 
lesion. All patients had indeterminate mammograms. 
Nine patients had 9 benign lesions in 9 breasts which were categorised as positive on 
our, Burak's and Taillefer's criteria. These included rest of 3 lesions with fibrocystic disease, 
one fibrotic lesion one inflammatory lesion. The patient with a clinically palpable inflammatory 
lesion, showed further 2 lesions in the same breast but were clinically impalpable and therefore 
could not be biopsied. These 2 lesions were also shown as positive on our, Burak's and 
Taillefer's criteria. The mammography was suggestive of benign disease in all these patients. 
Also included were 4 fibroadenomas. The mammography was suggestive of benign pathology in 
3 and indeterminate in one case. 
False positive SMM is not uncommon. Fibrocystic disease and fibroadenomas are the 
most common, like in our study. Khalkhali et al. [16] showed 11 false positive lesions out of 102 
benign breast lesions. These included 8 fibrocystic and 3 fibroadenoma lesions. Similarly Tiling 
et al. [84] showed 9 out of 53 false positive SMM scans. These included 4 fibroadenomas, 2 
fibrocystic disease, 2 inflammatory and one with papilloma. Burak et al. [14] showed 2 out of 14 
and Palmedo et al. [15] 1 out of7 false positive SMM. All were fibroadenomas. Taillefer et al. 
[18] had one out of 18 false positive SMM, a fibrocystic lesion, while Kao et al. [12] showed 6 
benign breast lesions with no false positives. 
It has been suggested that the "hypercellularity" of a breast lesion with or without atypia 
can accumulate Tc-99m MIBI, which results in false positive findings [16] . 
The rest of our study had 3 more patients with fibroadenomas, 2 patients with fat 
necrosis and one patient with 2 bilateral palpable fibroadipose tissue masses. All these showed 
negative SMM on our, Burak's and Taillefer's criteria. The mammography was suggestive of 
benign pathology in all these patients except in one case offibroadenoma which showed 
indeterminate mammography. In our study further 9 benign breast lesions showed negative 
SMM. These included 5 cysts and 4 normal adipose tissue. 
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These comparative results show no significant difference between the three studies. Our 
and Taillefer's results exactly match to each other. When compared to Burak's criteria, the 
number of true-positive SMM tend to improve slightly but at the expense of much higher 
false-positive rate because all indeterminate SMM scans, according to our and Taillefer's 
criteria, were regarded as positive using Burak's classification. 
Our method of data analysis for SMM results also constituted objective assessment using 
target to background ratio technique on each breast lesion detected on SMM. A semi-
quantitative method was therefore investigated to determine if the intensity of the lesion as 
compared to the rest of the breast activity (background) would help to differentiate between 
benign and malignant lesions. 
Quantitation has been suggested previously as an aid in differentiating between benign 
and malignant abnormalities [18]. Piccolo et al. [47] have studied semiquantitative analysis of 
Tc-99m methylene diphosphonate (MDP) uptake in breast lesions, using the normal breast to 
define the background region and generating time-activity curves. More recently, Dunnwald et 
al. [98] investigated the utility and reproducibility of semiquantitaive analysis on Tc-99m MIBI 
breast imaging and observed good separation between malignant and benign lesions, with some 
overlap occuring between small, low grade malignancies and benign lesions. Table 6.2 shows 
the comparison between their T/B ratio results and those obtained in the present study. 
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Table 6.2 Comparative Sestamibi Uptake Ratio Results 
Dunnwald et al. (98) Our Formal study 
Malignant Benign Malignant Benign 
Mean 4.2 1.9 2.9 2.0 
Std Deviation 2.3 0.7 1.5 0.6 
Range 1.9-9.4 1.0-2.7 1.0-6.9 1.3-3.0 
Our study showed a broader spectrum of T /B ratio overlap between benign and 
malignant lesions and could not be used to discriminate between cancerous and non-cancerous 
breast lesions. For benign lesions, our results were almost identical with those ofDunnwald et 
al. [98]. However, there were some differences between their method of determining T/B ratios 
and that used in our study. One difference was in the image analysis. They used the contralateral 
breast as the background, whereas we used the apparently normal breast tissue of the affected 
side for the same purpose. The other difference was that they used different sized box shaped 
region of interests (ROI), which were standardised for each area, for the lesion and background. 
On the other hand, we used identical sized box shaped RO Is for the lesion and the background 
in each patient and calculated total counts in each region to obtain T/B ratio . The results show 
that enough counts were obtained within each ROI for target and background. Total number of 
counts acquired for each target and background ROis and their ratios are shown in Table 5 and 6 
in Appendix B. 
Dunnwald and associates [98] used an additional quantitative measure by determining 
the ratio between the lesion and the right chest wall ()..,/CW). Both indices showed excellent 
intra-observer and inter-observer reproducibility. They observed that the L/CW ratio was less 
variable than the T/B ratio. They thought that diffuse uptake, which at times is visualised in 
apparently normal breast may result in more variability in the T/B ratio as compared to L/CW 
ratio method. We did not use the L/CW ratio in our study. Dunnwald et al. also suggested that 
these semiquantitative measures of tracer uptake reflected lesion characteristics and therefore, 
helped distinguish benign from malignant lesions and correlated with lesion size. 
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Tilling et al. [99] reported similar observations to ours. At low tumour to non-tumour 
ratios ( 1. 0-1 . 5) it was not possible to discriminate between benign and malignant breast lesions. 
Our results, however, suggested that this technique is not reliable to differentiate between benign 
and malignant breast lesions with T/B ratios under 3.0. Waxman [7] showed that numerous 
benign abnormalities have T /B ratios of greater than 1. 4 while small malignancies can show 
ratios ofless than 1.4. Our results as well those of others [98,99] were unlike those of Palmedo 
et al. [15], who showed that every lesion with a T/B ratio of 1.5 or more was histopathologically 
malignant. 
As discussed earlier, Burak et al. [14] and Taillefer et al. [18] have used different 
semiquantitive methods to evaluate breast masses with Tc-99m MIBI SMM. Burak et al. [14] in 
their study evaluated all images using a semiquantitative analysis technique which was graded 
from Oto 4 (described earlier in this chapter). Their results revealed that no breast lesion had 
activity greater than grade 3. Most of the malignant pathologies and 2 benign breast lesions had 
focal increased MIBI uptake of grade 2. They also found that there was no significant correlation 
between the pathological diagnosis of the malignant mass and the grade ofMIBI accumulation. 
Taillefer et al. [18] used semiquantitative analysis to determine the relative diagnostic 
certainty: graded from O (definitely normal) to 4 (definitely abnormal) as described earlier in this 
chapter. The ROis were placed over the primary breast tumour, surrounding apparent normal 
breast tissue, axillary lymph nodes (if detected on SMM) and ipsilateral lung to determine four 
activity ratios: breast tumour-to-normal breast tissue, breast tumour-to-axillary lymph nodes, 
normal breast tissue-to-lung and axillary lymph nodes-to-lung. Based on these diagnostic 
certainty gradations, 42 of the 43 true-positive cases were classified as definitely abnormal, 
whereas one was viewed as probably abnormal. Fifteen of the 17 true-negative cases were 
definitely normal and 2 were probably normal. Four different activity ratios were: primary breast 
tumour-to-normal breast tissue was 2.2 ± 0.7 (from 1.2 to 3.7); breast tumour-to-positive axillary 
nodes was 0.7 ± 0.2 (from 0.3 to 1.1); normal breast-to-lung was 0.3 ± 0.1 (from 0.1 to 0.6); and 
axillary nodes-to-lung was 0.8 ± 0.3 (from 0.6 to 1.5). 
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6.4. COMPARATIVE SENSITIVITY AND SPECIFICITY OF Tc-99m SESTAMIBI 
SCINTIMAMMOGRAPHY 
Our formal study has shown that Tc-99m MIBI scintimammography is more sensitive 
than mammography in detecting primary breast carcinoma but significantly less specific than 
mammography in differentiating between benign and malignant breast lesions. Similar 
sensitivities for Tc-99m MIBI have been found by most of the other investigators. However, as 
compared to our results of SMM, others have reported better specificity with Tc-99m MIBI in 
differentiating benign from malignant breast lesions (Table 6 .3). 
Our formal study showed a sensitivity of89.5% and specificity of 64% for SMM, as 
compared to mammography, which showed sensitivity and specificity of 80% and 100%. 
Palmedo et al. [100] showed similar findings for SMM. In their study, SMM showed a 
sensitivity of 91 % and specificity of 62% for detecting palpable breast carcinomas whereas 
mammography showed a sensitivity of 95% but specificity of only 10%. Their entire study 
consisted of 43 palpable and 13 non-palpable breast lesions and overall results for palpable and 
non-palpable lesions showed a sensitivity and specificity of 85% and 66%, respectively for 
SMM. The results of Kao et al. [12] who used Tc-99m MIBI in studying 38 women with 
palpable breast lumps, showed sensitivity of 84% and specificity of 100% in differentiating 
benign from malignant breast masses. Similarly Khalkhali et al. in a study with 147 patients, 
showed sensitivity of92.2% and specificity of 89.2% [16] and, in another study with 59 patients 
[17], reported sensitivity of95.8% and specificity of86.8%, in detecting breast carcinoma, both 
studies using Tc-99m MIBI. Taillefer et al. [18] have reported similar sensitivity and specificity, 
of91.5% and 94.4%, in detecting primary breast cancer using Tc-99m MIBI in 65 consecutive 
patients with suspicious breast lesions on clinical examination and/or with abnormal 
mammographies suggestive of malignancies. 
In summary, we have shown lower specificity for SMM than has been reported in the 
literature. The factors affecting specificity and sensitivity of SMM are discussed below. 
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Discussion 
6.4.1. Patient Selection 
In our pilot and formal studies, patient selection might account for the difference in 
specificity, when compared to other studies. We selected any patient with palpable breast 
lump/s rather than selecting only those patients who had breast lumps with suspicion for 
malignancy. Our selection criteria were therefore different from those in the other studies, 
where more patients with clinically and/or marnmographically suspicious breast lumps were 
selected. [15, 16, 18, 19]. Study populations high in patients with proliferative breast disorders 
like fibrocystic disease are more likely to have a relatively high false-positive rate [7]. The low 
specificity in our study was due to high number of false-positive scans. 
Our additional study differed from pilot and formal studies in two aspects. First, we 
included only patients with indeterminate mammography findings. Second, a lesion by lesion 
comparison of each breast lesion detected clinically and/or scintimarnmographically with 
biopsy results of a particular lesion was performed, which was not performed in the formal 
study. 
Sensitivity and specificity are critically dependent upon the selection of the patient 
population. Patient referral bias will influence the results. If clinicians refer only "difficult" 
cases for study, both sensitivity and specificity may differ from those obtained with an 
unselected pool of patients. In our formal study with 51 patients, 41 % of the women had 
malignant and 55% had benign breast lesions. In contrast, Kao et al. [12] had 84% of patients 
with malignant and 16% of cases with benign breast lesions in their series of 3 8 patients, and 
Taillefer et al. [18], in their study with 65 patients, had 72% of patients with malignant and 
28% with benign breast lesions. The relatively poor specificity in our Jonna! study may 
therefore be accounted for by the similar proportions of patients with benign and 
malignant breast lesions; the other studies [ 15, 16, 19] selected more patients with clinically 
and/or mammographically suspicious breast lesions, so favouring the likelihood of 
correctly detecting malignant lesions and decreasing the chances of false-positive scans. 
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6.4.2. Size of Lesion 
Another factor which might affect the sensitivity of SMM study is the size of the 
lesion. Small lesions are likely to be missed resulting infalse-negative SMM. In our 
formal study the false-negative rate was 3. 51 %. There were 2 patients with breast 
carcinomas who showed negative Tc-99m MIBI uptake. One of the patients had a small 
recurrent infiltrating ductal carcinoma, measuring 2 x 1 cm, with central haemorrhage. The 
possible cause of the absence ofMIBI uptake could be the relatively small size of the 
actual tumour. The other patient had a small nonpalpable lesion in the clinically normal 
breast, which was detected by mammography. The entire lesion (adenocarcinoma in situ) 
was only 10 mm in diameter with an even smaller focus of invasion (approximately 2 mm 
in diameter). The other (symptomatic) breast of the patient had 2 benign cystic lesions. 
Khalkhali et al. have reported two studies with different results for patients with 
nonpalpable breast lesions. In one study [ 17] they reported a low sensitivity of 50% but a 
specificity of 89.5% for detecting small nonpalpable breast lesions on Tc-99m MIBI 
scintimammography. In this study, only 2 out of21 breast masses were malignant, of 
which one was true positive and the other false negative on SMM, giving it a low 
sensitivity. In the other study [16], with a subgroup of 40 nonpalpable breast lesions, they 
showed SMM results with relatively high sensitivity of 88.8% and specificity of93 .5%. In 
this study there was only one case of false negative and 2 cases of false-positive SMM, 
resulting in high senisitivity and specificity, respectively. Waxman et al. have also 
reported low sensitivities of 50% [101] and 27% [102] in two studies with nonpalpable 
breast lesions. The results of these studies by Khalkhali and Waxman suggest that in 
general the sensitivity of SMM detecting nonpalpable breast lesions (mostly small lesions 
< 1 cm) is significantly less than that for palpable breast lumps. 
Aktolun et al. [13] showed that the smallest breast carcinoma detectable by SMM 
was 1.5 x 1 cm. Similarly, Palmedo et al. [15] and Peller [73] showed thatfalse-negative 
breast imaging with Tc-99m MIBI most frequently occurs in breast lesions which are less 
than 8 mm in diameter. These results suggest that with current gamma camera technology, 
with its limited resolution, very small lesions, less than 1 cm in diameter are less likely to 
be detected on SMM. 
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6.4.3. Location of Lesion 
Medially placed lesions may also create some difficulty in prone breast imaging as 
they are further away from the detector surface with more interposed breast tissue. 
Although, in our formal study, we were able to detect all palpable lesions ( 4 malignant and 
7 benign) located in the medial aspect of both breasts, they were more than 1 cm in size. 
Khalkhali et al. [16] have shown 3 patients (4 lesions), in their study on 147 patients (153 
lesions), who had medially placed breast lesions which escaped detection on prone lateral 
breast imaging. Three of these were palpable and one was a nonpalpable lesion but they 
were all less than 1 cm in the greatest diameter. All were malignant. 
6.4.4. Nature of Lesion 
Falsely positive Tc-99m MIBI uptake occurs in benign hypercellular breast lesions 
and inflammation [73]. In our formal study, 9 out of35 benign breast masses (in 33 
breasts) showed positive MIBI accumulation. The histological diagnoses were 
fibroadenomas in 4 cases,fibrocystic disease in 3 cases, inflammatory lesion in one and 
fibrosis in one case. The study reported by Khalkhali et al. [17], with 59 cases, showed 
false positive SMM in 5 patients (3 patients hadfibrocystic disease and 2 had 
fibroadenomas) . In all these patients hypercellularity with extensive florid hyperplasia and 
adenosis was a common pathologic feature. They suggested that the mechanism of MIBI 
uptake in fibroadenomas and fibrocystic disease could be related to "increased metabolic 
activity" of these lesions due to the augmentation of a cellular component in comparison 
to fibrous tissue. Similar results were reported in a study by Lu et al. [38], where 4 out of 7 
patients with fibroadenoma had increased uptake ofMIBI, all of which revealed active 
cellular hyperplasia. Kao et al. [12], in their study with 38 patients, showed no false 
positive MIBI uptake (all benign lesions were due to fibrocystic disease). This differs from 
most of the other studies done so far. 
Van Eijck and Krenning [103] have suggested that it is not possible to differentiate 
on scintimammography between epithelial hyperplasia, severe atypia, and sclerosing 
adenosis or microscopic intraductal and/ or infiltrating ductal carcinoma. Chiu et al. [104] 
have demonstrated that Tc-99m MIBI is sequestered within the cytoplasm and 
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mitochondria of cultured mouse fibroblasts. Their results suggested that normal and 
abnormal tissues with a large number of mitochondria per cell show higher Tc-99m MIBI 
uptake than tissues with fewer mitochondria. Gupta et al. [105] have demonstrated MIBI 
uptake in benign disease to be highly associated with the presence of proliferative 
changes, and speculated that the false positive MIBI breast uptake may reflect 
premalignant potential. However, more research in this area is needed to confirm these 
findings. Palmedo et al. [106] found most false positive studies to be associated with 
highly mitotic juvenile adenomas or local inflammation. Increased Tc-99m MIBI uptake 
has been reported in "metabolic active cells" of an in vitro cell culture line of normal 
tissues [11]. 
6.4.5. Other Factors 
It has been reported that mild, diffuse increased breast activity can be seen just 
prior to the onset of menses, especially in women under the age of30 years [73]. 
Unfortunately, we did not record data on menstrual cycle in our study. However, on 
retrospective analysis, we found that there were no women under the age of30 years 
among those selected. Among the patients with indeterminate SMM results, there were 3 
women between the ages of30 and 35 years and 4 women between the ages of36 and 46 
years, but none of the patients had pathology and therefore the results could not be 
attributed to the phase of the menstrual cycle. 
The large number of indeterminate SMM results also accounted for low specificity 
and accuracy in our formal study. They were mostly benign lesions with T/B ratios ofless 
than 2.0. We used different interpretative criteria as compared to other studies [16,84]. The 
visual interpretation of our indeterminate SMM studies corresponded to the scoring 
criteria for probably normal I negative (mild to moderate diffuse uptake with no region of 
focal increased uptake) in the studies conducted by Khalkhali et al. [ 16] and Tiling et al. 
[84]. We thought that our criteria for indeterminate could be more objective than the 
probably negative criteria used by others. We have observed that the relatively high 
numbers of indeterminate scans in our study were due to the difference in our 
interpretation of indeterminate SMM scans. If all indeterminate SMM scans in our series 
were considered as negative, the specificity would have increased to 76.3%. 
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Mammography is the only imaging procedure validated as useful in screening for 
breast cancer. In our formal study, mammographic evaluation correctly detected 73% (16 
out of22 of malignant breast carcinomas) in 21 breasts, with a sensitivity of 80% and very 
high specificity of 100%. Burak et al. [14] have shown, in their comparative study 
between Tc-99m MIBI and mammography, that the sensitivity and specificity of 
mammographic interpretation in the differentiation of malignant breast masses from 
benign lesions was 100% and 78%, respectively. Reported specificity of mammography 
varies from 15 to 75% [107-109]. 
6.5.1. False Positive Results and Positive Predictive Value 
As there were no false positive and only three false-negative mammograms in our 
formal study, it showed 100% values for the specificity and positive predictive value for 
mammography. Other studies have shown a general lack of mammographic specificity. As 
many benign lesions have significant density differences when compared with normal 
breasts, they result in false-positive mammography [7]. Calcifications revealed.on 
mammography may be the only evidence for malignancies within the breast and, as many 
benign conditions also result in calcifications, the false-positive rate has been extremely 
high for this technique [ 6]. It is important to note that, at our institution, the rate of false 
positive mammograms amongpalpable breast masses is generally very low. If the 
radiologist cannot decide whether the mass is benign or malignant, it is called 
indeterminate. Therefore, a benign mass with unclear features would be interpreted as 
indeterminate, rather than as malignant, unless it fulfils the criteria for a malignant lesion. 
The criteria for malignancy is a mass with irregularity and/or spiculation and/or 
microcalcification, which in difficult cases may be visible with special views (focal 
compression or magnification). Strict and specific interpretation criteria are used. In 
patients with mammographically suspicious breast lumps, an attempt is made to analyse 
the nature of the mass by the use of extra views, for example a repeat view, lateral view, 
focal compression and magnification views, in addition to standard cranio-caudal and 
medio-latera/ views. 
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Mammography is capable of detecting lesions of very small size, especially when 
calcifications are present [110]. Kopans [25] suggested that, despite the fact that 
mammography does not detect all cancers, a cancer that is detected by mammography 
alone is usually at a smaller size and earlier stage than a clinically apparent cancer, and 
this translates into a survival and mortality benefit. In one of our cases, mammography 
demonstrated a small, spiculated mass with microcalcification suggestive of a malignant 
lesion in a clinically and scintimammographically normal breast. Histopathological 
examination showed an adenocarcinoma in situ, the entire lesion measuring about 10 mm 
in diameter with a focus of invasion measuring approximately 2 mm in diameter. 
The basis of mammography is to find an abnormality which requires biopsy and to 
be able to exclude those that do not need further investigations. Although mammography 
frequently cannot be relied on to differentiate benign from malignant lesions, when certain 
morphological criteria are present it is extremely accurate [111]. Bird et al. [112] have 
reported sensitivity between 85-90% for screening mammography. The positive predictive 
value (the number of carcinomas diagnosed per number of biopsy results) of screening 
mammography ranges from approximately 15 to 75% [5]. 
6.5.2. False Negative Results 
It has been shown that a false-negative mammogram could cause a considerable 
delay in the decision to perform a biopsy in a patient subsequently shown to have 
carcinoma of the breast [26]. Mammography is often difficult to interpret in patients who 
have a scar within the breast from previous biopsy. 
In our formal study, 4 malignant breast lesions ( in 3 breasts) were falsely 
interpreted as benign on mammography. The first patient (patient 14) was found to have a 
recurrent infiltrating ductal carcinoma (2 x 1 cm) with central haemorrhage on excisional 
biopsy, but oil mammography no definite mass was seen, besides the scarring. Tc-99m 
MIBI SMM was also negative in this case. The second patient (patient 17) had a clinically 
solitary lesion in her right breast. SMM showed 2 ill-defined lesions close to each other 
and were regarded as indeterminate. Histology confirmed an invasive lobular carcinoma 
with another lobular ca. in situ, which was clinically not palpable, and was not detected on 
mammography. In the third patient, (patient 39) a 35 year old nulliparous woman with 
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positive family history of breast cancer, had mammographic features were suggestive of a 
benign lesion and SMM was indeterminate. However, histology confirmed a low-
malignancy type phylloides tumour, measuring 4 x 4 x 3 cm. In the last patient (patient40), 
mammography showed a vague density in the lower half of the breast with no specific 
signs of malignancy. This small breast lesion (1 x 1 cm on clinical examination) showed 
positive MIBI uptake consistent with malignancy. 
The false-negative rate of7% for mammography found informal study is 
representative of general results. At our institution, 10 to 15% of palpable breast lumps are 
missed or misdiagnosed. It is well established that mammography misses 5% to 15%.of 
cancers that are present and palpable at the time of screening, and as many as 20% of 
cancers become clinically evident within one year of a negative mammogram [113] . Bird 
et al. [112] showed a much higher false negative rate of 24% in detection of breast 
carcinoma by mammography. Similarly when Mann et al. [26] examined 165 patients with 
palpable breast masses that were histopathologically determined to be malignant. Only 
105 selected patients had mammography during their initial examination. Thirty-six 
patients were found to have false normal mammograms (34.2%). This group also 
concluded that mammography had certain limitations, particularly in young women with 
dense breasts. In another report from New Mexico [114] the false-negative rate for 
mammography was 45%. Many false-negative mammograms also occur in women whose 
tissues are not dense. 
There are several reasons why cancers are not shown by mammography. As in 
SMM, the importance of positioning cannot be overemphasized. According to Kopans 
[115], cancers will be missed if the breast is not properly positioned. There is also a 
significant danger of missing lesions near the chest wall. Similarly, if a neoplastic lesion is 
surrounded by tissue of similar x-ray attenuation and there is no architectural distortion or 
deposition of calcium, a large cancer may be invisible mammographically. Interpretative 
errors will always occur, but they can be minimised by proper training [115]. 
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6.5.3. Indeterminate Mammography Results 
Mammography has limitations in the differential diagnosis offibroadenoma as it 
may be indistinguishable from malignancy [ 116]. In our formal study 2 out of 7 
fibroadenomas showed indeterminate mammography masses. Burak et al. [14] 
demonstrated similar findings: in 4 out of 6 patients with fibroadenomas, mammographic 
evaluation could not differentiate benign from malignant mass. In our additional study of 
25 patients with indeterminate mammographic results, out of 22 benign lesions, there were 
5 fibroadenomas . 
It has been reported that in patients with mammographically dense breasts and with 
indeterminate opacities or microcalcifications, mammography is less reliable for 
differentiating between benign and malignant lesions [3,112] . In our formal study, there 
were 2 malignant lesions, one infiltrative lobular and one infiltrating ductal carcinoma (in 
2 breasts), and 3 benign neoplastic lesions, 2 fibroadenomas and one lipoma (in 3 breasts), 
which showed indeterminate masses on mammography. In the additional study with 25 
patients with indeterminate mammograms, there were 8 infiltrative ductal carcinomas (in 6 
breasts) and one squamous cell carcinoma. Of the 22 benign lesions, there were 5 
fibroadenomas, 4 fibrocystic disease, 3 cystic lesions, 2 fibrosis, 2 fibroadipose tissue, one 
lesion each of inflammatory tissue, fat necrosis and atypical ductal hyperplasia. In addition 
there were 3 lesions confirmed to be normal breast tissue. Holland et al. [ 117] studied 
patients with mammographically occult (nonpalpable) breast cancers. They felt that 
invasive ductal carcinomas are mostly associated with a strong desmoplastic reaction, but 
if the tumour is embedded in dense fibroglandular tissue the difference in density may not 
be enough to be appreciated mammographically as a focal mass. Similarly an invasive 
lobular carcinoma in dense breast can reach a size of several centimeters and still lack 
mammographic signs. Studies in the United States show that mammograms done on dense 
breasts have only a 20% rate of specificity and a positive predictive value of only 30% [5]. 
This means that only 1 in every 4 to 6 biopsies done to confirm malignant lesions in dense 
breasts would reveal malignancy. A more recent study, with 48 women with palpable 
abnormalities and grades ID and IV dense breasts according to American College of 
Radiology classification, showed the sensitivity and specificity of mammography to be 
82.2% and 46.1% respectively, whereas sensitivity and specificity of SMM in this group 
were 93 .7% and 90.6% respectively [118]. 
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Our study group consisted of 25 patients with 29 palpable and 2 nonpalpable breast 
lesions which were biopsied. There were further 10 nonpalpable lesions, detected on SMM 
and/or mammography which were not biopsied as the surgeon could not locate the exact 
site to biopsy in clinically normal breast. Of the breast lesions which were biopsied, we 
found that Tc-99m MIBI has a high sensitivity of 100% and a specificity of 63% for 
detecting breast cancer. Our results were comparable to those of Palmedo et al. [100] who 
studied a group of 56 patients with 43 palpable and 13 nonpalpable breast lesions. All 
abnormalities were dubious at mammography. For palpable breast lesions they showed a 
sensitivity of 91 % and specificity of 62%. The reason for relatively low specificity in our 
additional study and that of Palmedo et al. [100] might be the higher incidence offalse-
positive scans, especially fibroadenoma. 
Our additional study showed 7 out of22 (32%) false-positive SMM~ 5 of these 
were fibroadenoma. Palmedo et al. [100] showed similar observations. In another study, 
Prats et al. [86] showed a false-positive rate of 22% in their study of 31 
mammographically indeterminate breast lesions. In their study too, there was a high 
incidence offibroadenomas (4 out of 6 false-positive scans were fibroadenomas) . As 
discussed in earlier in this chapter, possible causes of false-positive SMM are 
hyperproliferative breast disorders, especially hyperplasia associated with atypia [7]. 
Conversely, Mekhmandarov et al. [85] showed no false-positive scans in a subgroup of 8 
patients with indeterminate mammographic results, including 2 nonpalpable 
fibroadenomas, which might be the reason for no MIBI uptake. 
Our additional study showed negative predictive value of 100% which supported 
the idea that SMM helps exclude breast cancer. In this study SMM detected all cases of 
breast cancer and none of the patients with negative SMM results had breast cancer. 
Therefore, it might be suggested that in lesions with low or indeterminate mammographic 
probability of malignancy, especially in palpable lesions(> 1cm in diameter), inclusion of 
Tc-99m MIBI SMM may have important consequences in reducing the number of 
biopsies. 
In the additional study, of the 2 nonpalpable lesions which were biopsied, one was 
scintimammographically positive and confirmed to be a ductal carcinoma, while the other 
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lesion consisted of a normal breast tissue and was indeterminate on SMM. Palmedo et al. 
[100] showed sensitivity of 60% and specificity of75% for nonpalpable lesions. 
Bombardieri et al. [8] showed a much highr prevalance of non palpable breast lesions in 
their study with 24 patients which showed only microcalcifications on mammography. 
They showed a specificity of 90% but a rather poor sensitivity of 50%. The reason for 
poor sensitivity could be explained by the fact that they only chose patients with clinically 
non demonstrable lesions with indeterminate mammographic lesions while in our study 
most of the non palpable lesions, detected on SMM and/or mammography were not 
biopsied. These results suggested that in the event of a positive SMM the likelihood of a 
breast cancer is definitely elevated. There were no false-negatives scans in the additional 
study. In our formal study, both mammography and SMM showed similar negative 
predictive values of 89%. 
It has also been shown that as breast tissue density increases, the sensitivity for 
detection of malignancy decreases [26,117,119]. Approximately 25% of women of all 
ages (especially young patients) exhibit dense breasts on mammography [3]. In the 
additional study with 25 patients, only 2 patients had mammographically dense breasts. 
Both lesions were benign on histology. One showed a negative SMM (inflammatory 
lesion) while the other was indeterminate on SMM (cyst). While in our formal series, 20 
patients had mammographically dense breasts. Of these, 9 breasts had histologically 
malignant and 11 breasts had benign breast masses. Of the 9 malignant lesions, 
mammography showed 3 false-negative and one indeterminate result as compared to 
SMM which showed 2 false-negative and one indeterminate result. Of the 11 benign 
lesions, mammography showed 2 indeterminate results as compared to one indeterminate 
SMM. But SMM showed 5 false-positive results whereas there were no false-positives in 
mammography 
6.6. COMPARISON BETWEEN SCINTIMAMMOGRAPHY AND 
MAMMOGRAPHY RESULTS 
On comparison of the results ofTc-99m MIBI scintimammography and 
mammography in this study, both methods demonstrated a high sensitivity for the 
detection of palpable breast carcinoma but mammography showed a clearly higher 
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specificity in comparison with scintimammography. Our results corresponded with the 
study by Palmedo et al. [100] in respect of scintimammography. They showed a sensitivity 
of91% and specificity 62% on SMM but their mammography results (sensitivity 95% and 
specificity 10%).were remarkably different as compared to our results. 
In patients with indeterminate mammographic opacities, the differentiation 
between benign and malignant lesions become less reliable [3,4]. These patients may 
benefit from a test that is independent of breast density or distortion. Khalkhali et al. 
[21,120] have suggested that SMM may be useful in patients in whom mammography is 
difficult to perform ( eg, in patients with fibroglandular dense breasts or breasts with 
scarring due to biopsy or lumpectomy. Their results showed a higher sensitivity and better 
specificity with SMM as compared to conventional mammography in correct 
identification of malignant and benign lesions in patients with indeterminate 
mammographic results. 
The results of our additional study also support the idea that in patients with 
indeterminate mammographic findings, the use of SMM scan may reduce the number of 
unnecessary biopsies, by about 50%. There were no false-negative SMM in this study and 
as a negative scan is more indicative of a benign aetiology, this might prove to be very 
useful in diagnosis of patients with suspect mammograms. 
The use ofTc-99m MIDI SMM can potentially define a population of patients in 
whom the presence of a negative SMM study is highly suggestive of benign etiology for 
palpable breast masses since the sensitivity for detecting breast carcinoma is high. But the 
possibility of false-negative scintigraphic diagnosis must be kept in mind as small 
tumours, particularly below 1 cm diameter and carcinomas in situ are poorly detectable by 
SMM. The presence of a positive SMM test would justify/encourage a biopsy due to high 
sensitivity for detecting carcinoma. 
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6.7. AXILLARY LYMPH NODE DETECTION 
Axillary lymph node resection is an important part of staging breast cancer. The 
status of axillary lymph nodes also plays a key role in therapeutic decisions and prognosis 
of the disease [121]. Presently, axillary lymph node status is determined either clinically or 
pathologically. The clinical evaluation of lymph node status is not reliable as, among 
patients with clinically negative axillary lymph nodes, up to 39°/o may have histologically 
positive nodes. Conversely, among patients with clinically palpable lymph nodes thought 
to be positive, 38% would have normal histological results [122]. 
A complete axillary node resection requires general anesthesia and added expense 
and risks. According to Khalkhali et al. [22], the expense and extent of surgical staging 
exceeds that of surgical treatment of the primary cancer. None of the anatomic imaging 
modalities (i.e., CT, l\1RI and ultra-sound) can determine the presence or absence of 
axillary lymph node disease with reasonable sensitivity and specificity. Commonly, lymph 
node involvement as determined microscopically consists of only a few malignant cells, 
without structural distortion within the lymph node. 
The strategic importance of determining the degree of lymph node involvement in 
the breast region prior to surgery has greatly stimulated the use of sentinal node imaging 
(lymphoscintigraphy) with colloids in the last decade [123,124]. This technique is entirely 
different from Tc-99m MIBI and other tracers used for detecting breast cancer and has 
shown variable sensitivity ranging from 60% to 70% and the specificity from 65% to 90% 
[125-127]. It remains to be seen whether nuclear medicine imaging (PET or SPECT) can 
help to differentiate between benign and cancerous lymph nodes. False-positive results 
with nuclear medicine imaging may occur in lymph nodes with inflammatory changes. 
Taillefer et al. [18] showed metastatic lymph node involvement in 19 of 41 
patients. The sensitivity of SMM in detecting metastatic axillary lymph nodes was 84.2% 
and the specificity was 90.9%. Another study [42] using Tc-99m MIBI showed sensitivity 
of 66% and specificity of 100%. Khalkhali and Diggles [ 128] have reported sensitivity and 
specificity of 60% and 90%, respectively , using SMM in diagnosing axillary lymph node 
metastases. Burak et al. [14] have shown that the sensitivity of Tc-99m MIBI to detect 
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axillary metastases is low (57%), unless enlarged lymph node groups are present. SPECT 
imaging may improve the axillary node statistics [7]. 
Our formal study showed a sensitivity of 50% (3 true positive and 3 false negative) 
and specificity of75% (15 true negative and 5 false positive) in the detection oflymph 
node involvement by SMM. There were 2 patients with highly positive SMM and 
mammographic features of lymph node involvement, but histopathological results were 
normal. We feel that these 2 cases lowered/dropped the specificity of our results. The low 
sensitivity could be due to early lymph node involvement with few malignant cells in 
some patients, as a low number oflymph nodes ( 6 out of 33 lymph nodes in 3 patients) 
were shown to be involved on histopathology. The SMM showed substantially better 
sensitivity to detect metastatic lymph node involvement as compared to mammography, as 
mammography could detect lymph node involvement in only one out of 6 patients with 
axillary metastases. 
Krag et al. [121] have described the use of a gamma probe to detect axillary lymph 
node metastases. Using a gamma detector to locate the site of the sentinal lymph node, 
they evaluated 22 women with proven breast cancer. Their results suggested that it is 
technically feasible to localise a sentinal lymph node using a gamma probe and Tc-99m 
sulphur colloid, in a majority of breast cancer patients. It could help the surgeon to avoid 
complete axillary lymph node dissection in patients with small primary tumours, in whom 
the likelihood of a micrometastases is very small. 
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Conclusion and Recommendations 
The following conclusions and recommendations arise from this study. 
With regard to methodology, we suggest that fractionation ofMIBI can be easily 
performed in a nuclear medicine laboratory. Fractionated MIDI can be safely used, 
without compromising the quality of the scan, for nuclear medicine studies, including 
breast imaging, and this significantly reduces the cost of the sestamibi. 
The technique of prone breast imaging provides excellent separation of the left 
breast deep structures from the myocardium and separation of the right breast from the 
liver. Relaxation of the pectoralis muscle improves the resolution of small deep-seated 
lesions. Semiquantitative analysis of sestamibi breast imaging may be helpful in 
objectively interpreting imaging results in patients with T/B uptake ratios of 3.0 or more. 
Our results and those of others [38] suggest that delayed imaging does not provide 
any additional information as compared to the early images. Therefore imaging could be 
performed from S to 10 minutes after injection. 
Based on this research, we believe that mammography is the basic screening 
modality for palpable breast masses and cannot be replaced by MIBI breast imaging. Our 
results suggest that the addition of Tc-99m MIDI scintimammography to mammography 
is of limited value when the mammogram shows a high probability of malignancy. 
However, Tc-99m MIBI scintigraphy is probably of value in the evaluation oflesions 
shown by mammography to have moderate and low probability of malignancy and may 
allow the reduction of unnecessary biopsies indicated by mammography. Therefore Tc-
99m MIBI SMM might provide additional information on the differentiation of malignant 
pathologies from benign lesions in patients with palpable breast anomalies. 
Tc-99m MIBI breast imaging may have advantages over mammography in patients 
with dense breasts and make a significant contribution to clinical management in patients 
with suspected breast abnormalities [129]. Tc-99m MIDI study may improve the 
specificity of detection especially in women with a high risk for the development of breast 
cancer and who have suspect mammograms. 
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SMM has a clinical role in the evaluation of mammographically negative or 
indeterminate lesions, especially palpable lesions not clearly categorised by 
mammography and in dense breast tissue. As a negative MIDI study is highly indicative of 
a benign aetiology, the additional information given by a negative Tc-99m MIDI SMM in 
an indeterminate mammograhic lesion is very useful in diagnosis. While, the possibility of 
false-negative SMM diagnosis must be kept in mind, clinical follow up and routine 
mammography would be suggested in cases with negative SMM results. 
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111 
Pi.lot Study 
1. METHODOLOGY 
1.1. PURPOSE 
The main objective of this study was to determine whether the selected imaging 
technique was practical. 
1.2. SAMPLE SELECTION 
The study population consisted of 11 women between the ages of 16 and 69 years 
with a mean age of 43 years. 
The patient selection and exclusion criteria were the same in this study to those 
applied for the formal study. 
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1.3. PROCEDURE 
Locally produced sestamibi (Myotek) by the AEC of South Africa was used for 
scintimammography (SMM). Each vial ofl\.1IBI was fractionated into 10 fractions and 
quality control was performed on each fractionated dose, using exactly the same methods 
that were used in the formal study. The radiochemical purity ofTc-99m l\.1IBI was always 
more than 90% (range 90-98%). 
1.3.1. Scintimammography Procedure 
A gamma camera (GE 400 AC Starcam) equipped with low energy, high 
resolution, parallel hole collimator was used for imaging. The imaging procedure was 
explained to each patient before scanning. 
An intravenous injection of a standard dose of 740 MBq ofTc-99m l\.1IBI was 
given in the arm contralateral to the affected side. 
1.3.2. Patient and Camera positions 
Two sets of planar images were acquired of lateral and posterior oblique (25°) 
views on each breast. On delayed imaging, additional anterior chest/axillary views were 
acquired on both sides in supine position. These views were always acquired after lateral 
and posterior oblique views. 
Patients were requested to undress down to the waist. Both breast and axillae were 
examined for palpable lesions before starting the imaging procedure. 
Lateral and Posterior oblique views were acquired in the prone position. The 
patient lay in the prone position on the imaging bed. The breast to be imaged was 
positioned by moving that side of the chest across the edge of the bed so that the breast on 
that side hung freely dependent from the bed and avoided any compression of the breast 
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by the edge of the bed. The patient lay on the wider lower part of the bed from the hips 
down as it helped in stabilising the patient's posture. The sternum of the patient was 
positioned along the edge of the bed which was padded to be comfortable. A pillow was 
placed under the head of the patient for support. The patient's arm on the side to be 
imaged was straightened above the head, without tilting the back, and keeping the 
shoulder girdle relaxed. 
For lateral and posterior oblique views, patient position on the bed remained 
unchanged. For the lateral view, the surface of the detector was positioned vertically, 
parallel and very close to the pendulous breast. For the posterior oblique view the detector 
was tilted to 25 degrees keeping the entire breast in the field of view. Ipsilateral axilla and 
adjacent anterior chest wall were also included in the field of view to detect any lymph 
node involvement and deep seated lesion in the breast or chest wall, respectively. 
For the anterior chest/axillary view, imaging was done with the patient in a supine 
position. The patient lay in the middle of the bed with her head on a pillow and the arm on 
the side to be imaged, abducted, bent at the elbow and hand placed under her head. The 
bed was moved across to the side in order to include the entire breast and the axilla in the 
field of view. The detector was positioned facing the anterior chest from above and close 
to the breast. 
The nipple was marked with a radioactive marker. The marker was made from the 
needle of the syinge used for injection of the tracer. The needle was removed from the 
syringe and its base, containing some residual activity, was sealed with cellophane tape. A 
marker image was taken at the start of each view. Marker position was recorded with a 
"cross +" using the image marking facility of the camera. The radioactive marker, based 
on the ECG electrode was developed later in the pilot study and was used in a few patients 
during this study and in all patients in the formal study. 
Other acquisition parameters of the study included: 
1. An image zoom of factor 2 for lateral and posterior oblique views to magnify 
the breast image and to exclude unnecessary activity from the heart and liver from the 
field of view. 
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2. The images were acquired in a 256 x 256 matrix. The photopeak was centered 
over 140 ke V with a I 0% window on its either side. 
Two sets of images were acquired on each breast. The first set started at 5 minutes 
after the injection of the tracer and the second set commenced immediately after the first 
set of images had been recorded. The images in the first set were acquired at 5 minutes per 
image and in the second set at IO minutes per image. The anterior chest / axillary views 
were only performed with the second set of images at IO minutes per image. 
The injection site was always kept out of the field of view. Patients were allowed 
to rest for few minutes after each set of images was completed. 
After acquisition had been completed, the study was transferred to another 
computer terminal to make hard copies of all the images. All images were interpreted 
visually both on the computer screen and on the hard copies, to detect any abnormal 
increased activity of the tracer in the breast or axilla. The objective assessment was 
performed by semiquantitative analysis using target to background (TIB) ratio, as 
described below. 
1.3.3. Statistical Methods 
The intensity ofMIBI uptake within the visually detected breast lesion was 
evaluated by determining the TIB ratio. Either the lateral or posterior oblique view of the 
breast was selected to draw the region of interest, depending upon which view better 
illustrated the lesion. 
The total counts obtained in each view, in both sets of images, were recorded. In 
addition, on lateral view, irregular region of interest were drawn around each breast, 
excluding the chest wall. The total counts in each irregular ROI and area in pixels were 
used to calculate counts per pixel for each breast. The TIB ratios were used as a 
quantitative measure to determine whether it could help to distinguish between true 
malignant and scintimammographically false malignant/ indeterminate breast lesions 
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(False Positives). This recorded data can be seen in Table 4 of Appendix B. 
A square region of interest was drawn within the outline of the breast lesion. 
Another region of the same dimensions was drawn over the normal breast tissue of the 
same breast. The background region was drawn at a variable distance, ranging from 0.5 to 
1.5 cm from the target region, in different patients. In breasts with more than one target 
lesion, a common background region was drawn in the same breast, at approximately the 
same distance from the target regions. TIB ratios were the ratios of the total counts for 
each region of interest. 
1.4. SCAN INTERPRETATION 
Visual assessment of the SMM scans was done on each set of images. The breast 
lesions were classified as positive, negative or indeterminate. The following criteria were 
used: 
POSITIVE: 
NEGATIVE: 
INDETERMINATE: 
A well defined area of increased uptake 
with an intensity greater than the normal 
surrounding breast tissue. 
No focal increased uptake in the breast. 
An ill defined area of low-grade 
increased uptake which is unclassifiable 
as benign or malignant~ as there is 
increased uptake, it cannot not be termed 
normal, but the uptake is not intense or 
well enough defined to be classified as 
malignant. 
All studies were evaluated by the researcher and another experienced nuclear 
medicine physician. A third observer, another nuclear medicine physcian, was referred to 
in cases of disagreement. 
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2. RESULTS 
Eleven patients were evaluated in this trial. 
2.1. CLINICAL EXAMINATION 
Clinically there were 12 palpable lumps in 12 breasts in 11 patients. Five patients 
presented with solitary masses in their right and 5 patients in their left breasts. One patient 
had bilateral breast masse~. The number and distribution of palpable breast lesions are 
shown in Table 2.1. 
Of the total number of patients one had a possible tumour recurrence after the 
surgery, radio and chemotherapy and one had a positive family history of breast cancer. 
The youngest patient was a 16 year old nulliparous girl. 
Individual patient details are shown in tabulated form in Table 1 of Appendix B. 
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Table 2. J. Number and Distribution of Lesions in Each Breast on Clinical 
Examination. 
RIGHT BREAST LESIONS 
Upper Outer Quadrant 4 
Upper Inner Quadrant 1 
Lower Outer Quadrant 0 
Lower Inner Quadrant 1 
Other 0 
TOTAL 6 
LEFT BREAST: LESIONS 
Upper Outer Quadrant 3 
Upper Inner Quadrant: 1 
Lower Outer Quadrant: 1 
Lower Inner Quadrant: 1 
Other: 0 
TOTAL 6 
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2.2. BIOPSY RESULTS 
All 12 palpable breast lesions had biopsies. 
There were 4 malignant lesions in 4 breasts and 8 benign lesions in 8 breasts. A 
patient (patient 8) had one palpable lesion in each breast. Both were confirmed to be 
fibroadenomas . On SMM, another lesion was detected in the left breast which was 
clinically not palpable and therefore was not biopsied. 
Both patients with possible tumour recurrence and positive family history of breast 
cancer had benign lesions (fat necrosis and fibrosis, respectively). The histopathological 
results are listed in Table 2.2. 
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Table 2.2: Histopathological Results of 12 Palpable Breast Lesions. 
IDSTOPATHOLOGICAL FINDINGS LESIONS BREASTS 
Malignant Tumours : 
Infiltrative Duct Ca. 3 3 
Mucinous Ca. 1 1 
Benign Tumours : 
Fibroadenoma 4 4 
Other Benign Lesions : 
Fat Necrosis 1 1 
Fibrosis/Sclerosis 2 2 
Mastitis 1 1 
Total 12 12 
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2.3. MAMMOGRAPHY RESULTS 
Nine out of eleven patients underwent mammography. 
Four patients showed positive mammography suggestive of malignancy, while one 
patient had negative mammography suggestive of a benign lesion. In 2 cases the results 
were indeterminate. The patient with a positive family history of breast cancer showed a 
negative mammography result. 
Two patients did not have mammography. One of the patients (patient 8) 
presented clinically with bilateral breast lesions and refused to have mammography, but 
later returned for the operation ( excision biopsy was performed). The other patient had a 
solitary breast lesion clinically and has had prior biopsy with the diagnosis of 
fibroadenosis, so the radiologist deemed mammography would not be of further benefit. 
2.4. TECHNETIUM-99m MIBI SMM RESULTS 
All 11 patients had SMM. Both early and late images were evaluated visually and 
by semi-quantitative method. 
All 4 lesions in 4 breasts with histopathologically confirmed breast cancers, 
showed positive SMM. There were no negative SMM scans in patients with malignant 
breast lesions. 
Of the 8 palpable benign lesions in 8 breasts, 6 lesions had negative SMM scans 
suggestive of benign pathology, while 2 palpable lesions noted in a patient with bilateral 
breast lumps showed positive SMM. Both these lesions were shown to be fibroadenomas 
on biopsy. Another lesion was detected in the left breast of the same patient as positive 
SMM. This lesion was clinically nonpalpable and was not biopsied. 
There no indeterminate SMM scans. 
The Tc-99m MIBI scintimammography results are illustrated in Table 2.3. 
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Table 4 of Appendix B shows the total counts obtained in each view in both sets of 
images. Counts per pixel in right and left breast and area in pixel, were calculated for each 
patient. Comparison of distribution of counts per pixel of right versus left breast showed 
more counts per pixel in a breast due to a lesion (increased MIBI uptake) or occasionally 
due to diffuse increase uptake in that breast as compared to the contralateral side, as a 
normal variant. 
Target to background ratios were calculated on all breast lesions in both sets of 
images. The early set of images always showed higher TIB ratios as compared to the late 
set. There was almost no difference in delineation of lesions seen on either sets of images. 
Figure 2.1 illustrates the difference in T/B ratios in early and late sets of images on 
SMM. 
The evaluation of SMM by delayed breast imaging did not alter our results when 
compared with early images. 
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Table 2.3. Scintigraphic Findings Co"elating With Histopathological Results. 
Histological Number of Tc-99m MIBI uptake 
Diagnosis Lesions Positive Negative Intermediate 
Infiltrative Ductal 3 3 0 
Ca 
Mucinous Ca 1 1 0 
Fibroadenoma 4 2 2 
Fat Necrosis 1 0 1 
Fibrosis/Sclerosis 2 0 2 
Mastitis 1 0 1 
Note: A clinically non palpable lesion detected only on SMM (patient 8) was not 
biopsied and there/ ore is not included in this table. 
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2.5. BIOPSY VS MAMMOGRAPHY RESULTS 
Table 2. 4. Summary of Histopathological and Mammography Results 
HISTOLOGY 
Malignant Benign 
Positive 4 0 
MAMMO Negative 0 3 
Indeterminate 0 2 
All 4 patients with histological diagnosis of malignant breast lesions showed 
positive mammography results. Two patients with 3 benign lesions (including the patient 
with bilateral breast lumps) did not undergo mammography, as described earlier; while 3 
patients showed negative mammography suggestive of benign lesions. Rest of 2 lesions 
showed indeterminate mammographic features . 
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2.6. BIOPSY VS SCINTIMAMMOGRAPHY RESULTS 
Table 2. 5. Summary of Histopathological and Tc-99m MIBI SMM Results. 
HISTOLOGY 
Malignant Benign 
Positive 4 2 
Negative 0 6 
Indeterminate 0 0 
In total, 10 out of 11 patients showed concordant results between SMM and 
histology. 
All 4 patients with histological diagnosis of malignant breast lesions showed 
positive SMM results. Six patients with benign breast lesions (2 neoplastic and 4 non-
neoplastic) showed negative SMM results. Increased MIBI uptake was noted in 
2 breast lesions in a patient with bilateral fibroadenomas. Another lesion was noted on 
SMM in the left breast of the same patient. This lesion was clinically nonpalpable and was 
not biopsied. 
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2.7. BIOPSY VS SCINTIMAMMOGRAPHY VS MAMMOGRAPHY RESULTS 
The comparative results of SMM and mammography were compared with biopsy 
results which is considered as a gold standard.These results are shown in Table 2.6. 
Table 2. 6 Comparison Between Histopathological, Tc-99m SMM and mammography 
Results 
Lesions Histology SMM Mammo Comment 
4 Malignant Positive Positive 
3 Benign Negative Negative 
2 Benign Negative Indeterminate 
1 Benign Negative Not Done Fibroadenoma 
2 Benign Positive Not Done Fibroadenoma 
2.8. AXILLARY LYMPH NODE INVOLVEMENT 
Metastatic ipsilateral axillary lymph node involvement was confirmed in 2 patients 
on biopsy. In each patient, out of 8 lymph nodes explored, 2 showed metastatic 
involvement. SMM did not demonstrate lymph node involvement in any of the patients 
whereas mammography demonstrated positive metastatic involvement of lymph nodes in 
one case. 
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3.REMARKS 
This study demonstrated that the activity of the breast lesion was always higher 
than the apparent normal breast tissue and that the addition of late images were not helpful 
in terms of lesion detectability. Thus, we suggest that early imaging for the detection of 
breast carcinoma was preferable as there was no difference in delineation of lesions seen 
on the scan between the two sets of images. In fact, the late images showed lower T/B 
ratios in all the lesions as compared to the early images (see Fig 2.1). 
Therefore a revised acquisition technique was implemented for the formal study 
with modified protocol in which the late images were excluded. The rest of the protocol 
remained unchanged. 
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